{
  "$schema": "folio-library-entry/v1",
  "id": "10665-360948",
  "blocks": [
    {
      "id": "library/10665-360948/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 8,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "CONSOLIDATED GUIDELINES ON \nPERSON-CENTRED \nHIV STRATEGIC \nINFORMATION\n STRENGTHENING ROUTINE DATA \nFOR IMPACT\nCONSOLIDATED GUIDELINES ON \nPERSON-CENTRED \nHIV STRATEGIC \nINFORMATION\n STRENGTHENING ROUTINE DATA \nFOR IMPACT\nConsolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact\nISBN 978-92-4-005531-5 (electronic version) \nISBN 978-92-4-005532-2 (print version)\n© World Health Organization 2022\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-\nShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https:",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's 2022 consolidated guidelines on person-centred HIV strategic information, with ISBNs and Creative Commons licence terms. It also contains a detailed table of contents running through chapters on prevention, testing, treatment, data systems and priority indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 8,
      "pageEnd": 12,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "The World Health Organization (WHO) gratefully acknowledges the contributions of many \nindividuals and organizations to these consolidated guidelines.\nWHO STAFF AND CONSULTANTS\nShona Dalal coordinated the overall guideline process with Diana Faini, Annette Gerritsen, \nHiwot Haille-Selassie, Bradley Mathers, William Probert, Francoise Renaud and Jane Rowley \nunder the leadership of Daniel Low-Beer, Unit Head, and Meg Doherty, Director (Department \nof Global HIV, Hepatitis and Sexually Transmitted Infections Programmes). The following \nindividuals provided technical review and content inputs: Wo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The acknowledgements of the consolidated HIV strategic information guidelines, naming WHO staff, external reviewers and contributing organizations. It also notes funding from the US government through USAID and CDC.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations and acronyms",
      "pageStart": 12,
      "pageEnd": 15,
      "target": "../sections/sec-001-abbreviations-and-acronyms.md",
      "narrative": null,
      "content": "AEM\nAIDS Epidemic Model \nAIM\nSpectrum AIDS Impact Model\nAIS\nAIDS Indicator Surveys\nANC\nantenatal care \nART\nantiretroviral therapy\nARV\nantiretroviral \nBBS\nbio-behavioural survey (also called IBBS – integrated bio-behavioural survey)\nCAB-LA \nlong-acting injectable cabotegravir \nCAG\ncommunity ART group\nCDC\nUnited States Centers for Disease Control and Prevention\nCHW\ncommunity health worker\nCLM\ncommunity-led monitoring\nCPT\nco-trimoxazole preventive therapy\nCRVS\ncivil registration and vital statistics \nCTX\nco-trimoxazole\nDAK\ndigital adaptation kit\nDDCC\ndigital documentation of COVID-19 certificates",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations and acronyms used in the HIV strategic information guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Glossary",
      "pageStart": 15,
      "pageEnd": 19,
      "target": "../sections/sec-002-glossary.md",
      "narrative": null,
      "content": "Active TB disease case A person who exhibits signs or symptoms of active disease and tests \npositive for Mycobacterium tuberculosis on smear examination, culture or a molecular WHO-\nrecommended rapid diagnostic test such as Xpert MTB/RIF, or who is clinically diagnosed as a \nTB case by a clinician or other medical practitioner with a decision to treat with a full course of \nTB treatment. This is synonymous with confirmed TB case.\nAdvanced HIV disease For adults, adolescents and children five years and older, advanced \nHIV disease is defined by a CD4 cell count <200 cells/mm3 or a WHO clinical",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A glossary of terms used in the HIV strategic information guidelines, from active TB disease and advanced HIV disease through aggregate data to key and vulnerable populations. It defines clinical, programme and data system concepts relevant to person-centred HIV monitoring. Definitions are generally given for both clinical and data-management purposes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 19,
      "pageEnd": 22,
      "target": "../sections/sec-003-executive-summary.md",
      "narrative": null,
      "content": "Person-centred data for improved health outcomes and impact\nNow into the fourth decade of the global response to HIV, a wealth of data exists on \nwhere and among whom new infections occur, methods of prevention and treatment, viral \nsuppression and programme coverage and performance. Yet, substantial gaps in the response \nremain. New infections are occurring at a rate far above global targets, and, while treatment \ncoverage is high in many settings, retention in care continues to be a challenge, and late \ndiagnoses persist. To help address such challenges, these consolidated strategic informat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The executive summary of the consolidated HIV strategic information guidelines notes that despite abundant data, new infections remain above targets and retention and late diagnosis are problems. It explains that the guidelines focus on individual-level routine data to strengthen person-centred services and linkage to prevention and treatment. It also notes the inclusion of data on STIs, TB, viral hepatitis and cervical cancer in HIV data systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary recommendations",
      "pageStart": 22,
      "pageEnd": 25,
      "target": "../sections/sec-004-summary-recommendations.md",
      "narrative": null,
      "content": "Chapter 2 – Person-centred HIV prevention monitoring\nNEW \n1. \t\u0007The collection of a minimum dataset of individual-level data elements on HIV prevention \ninterventions is recommended to measure interventions received and health outcomes among \nindividuals seeking HIV prevention.\nNEW \n2. \t\u0007Individual-level data on HIV prevention should be used, alongside other available data sources, \nto strengthen the measurement of:\n\t\na) \u0007the coverage of interventions provided to populations affected by HIV, to increasingly measure \nindividual people reached rather than services delivered\n\t\nb) \u0007prevention impac",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the guidelines' recommendations by chapter, starting with new recommendations on collecting individual-level HIV prevention data to measure coverage and impact. Further recommendations cover testing, treatment, data systems and use of digital tools. It closes by stressing confidentiality and security of personal data, given elevated risks for key populations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary list of priority indicators",
      "pageStart": 25,
      "pageEnd": 31,
      "target": "../sections/sec-005-summary-list-of-priority-indicators.md",
      "narrative": null,
      "content": "Programme indicators\nRef.no\nShort name\nIndicator definition\nCondom programming\nPRV.1\nCondoms distributed\nTotal number of condoms distributed during the \nreporting period\nPre-exposure prophylaxis (PrEP)\nPRV.2\nTotal PrEP recipients\nNumber of people who received PrEP at least once \nduring the reporting period \nPRV.3\n(NEW)\nPrEP coverage\n% of people prescribed PrEP among those identified as \nbeing at elevated risk for HIV acquisition \nPRV.4\n(NEW)\nVolume of PrEP prescribed \nTotal volume of PrEP product prescribed\nPost-exposure prophylaxis (PEP)\nPRV.5\n(NEW)\nNumber of PEP recipients\nNumber of people p",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A summary table of priority indicators from WHO's 2022 consolidated guidelines on person-centred HIV strategic information, giving each indicator's reference number, short name and definition, with new and updated indicators flagged. It spans HIV prevention (condoms, PrEP, PEP, needle–syringe programmes and more), testing, treatment and viral load, vertical transmission, and differentiated service delivery. It also covers TB–HIV, related infections such as cervical cancer, incidence and mortality, and ends with indicators on avoidance of health care due to stigma and discrimination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 1 – Introduction",
      "pageStart": 31,
      "pageEnd": 32,
      "target": "../sections/sec-006-chapter-1-introduction.md",
      "narrative": null,
      "content": "INTRODUCTION\n1\n1.1\t Background and rationale\b\n2\n1.1.1 Evolving data needs for a new phase of the HIV response\b\n2\n1.1.2 Advancing from aggregate to individual-level data use\b\n3\n1.1.3 Integration of sexually transmitted infections, viral hepatitis, tuberculosis \nand cervical cancer into HIV reporting systems\b\n6\n1.1.4 Data considerations for key populations\b\n6\n1.1.5 Strengthening the use of data from other sources \b\n8\n1.2\t What’s new in this consolidation of WHO strategic information guidelines\b\n10\n1.2.1 Data system maturity for use of person-centred data \b\n11\n1.3\t Objectives and guiding principl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The contents listing for Chapter 1, the introduction, covering background, evolving data needs, individual-level data, integration of related infections, key populations, new features, objectives, development process and intended audiences.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background and rationale",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../sections/sec-007-11-background-and-rationale.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evolving data needs for a new phase of the HIV response",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../sections/sec-008-111-evolving-data-needs-for-a-new-phase-of-the-h.md",
      "narrative": null,
      "content": "Enormous gains have been made in the HIV response over the four decades since the first \nidentification of the virus. Treatment has expanded to an estimated 28 million people of the 38 \nmillion people living with HIV in 2021, and eight countries have achieved the UNAIDS 90–90–90 \ntargets (1). These gains have increased life expectancy and enabled people living with HIV to \nlead healthier lives.\nAs large numbers of people living with HIV are followed over time, new challenges have come \nto the fore. Loss to follow-up from antiretroviral treatment (ART) is one such challenge. It has \nimplication",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes progress in the HIV response, with about 28 million of 38 million people living with HIV on treatment in 2021, and new challenges such as loss to follow-up and slow declines in new infections. It argues that routine data systems must evolve to identify gaps faster, alongside surveys, studies and models, while keeping the people whose data are gathered safe and their data secure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Advancing from aggregate to individual-level data use",
      "pageStart": 33,
      "pageEnd": 36,
      "target": "../sections/sec-009-112-advancing-from-aggregate-to-individual-level.md",
      "narrative": null,
      "content": "The major source of strategic information used to monitor the HIV response in the health sector \nis aggregate routine facility data. Understanding the strengths and limitations of this type \nof data is critical to their proper use and interpretation. Individual-level data, as reflected in \nprimary data collection tools such as patient records, have always been viewed as critical to \npatient care, supporting the longitudinal monitoring of clients as they access services over time. \nAt the client–provider interface, individual-level data can improve the quality and continuity \nof care that a cli",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Contrasts aggregate facility data with individual-level data, explaining that person-level records linked by unique identifiers improve continuity of care, reduce duplicate counts and allow more accurate automated reporting. It describes how paper-based and electronic reporting may run in parallel while systems mature and be combined at subnational or national level. It stresses checking completeness and quality and the principle of collecting data once and using it many times.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p034",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../figures/vfig-p034.webp",
      "narrative": "draft",
      "content": "Fig. 1.1, a concentric circle diagram titled 'Harnessing person-centred data to improve HIV services and impact'. A human figure at the centre is surrounded by a ring labelled HIV prevention, HIV treatment and Related infections; the next ring lists Monitor impact, Improve quality of services, Identify HIV testing, prevention & treatment needs, Improve integration, and Ensure data privacy, confidentiality, & security. The outer ring reads 'Improved health' at the top and 'Individual-level data' at the bottom.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Integration of sexually transmitted infections, viral hepatitis, tuberculosis and cervical cancer into HIV reporting systems",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../sections/sec-010-113-integration-of-sexually-transmitted-infectio.md",
      "narrative": null,
      "content": "tuberculosis and cervical cancer into HIV reporting systems\nEvery day, worldwide, people acquire more than 1 million curable sexually transmitted \ninfections (STIs). More than one in every seven women is estimated to be infected with human \npapillomavirus (HPV), and more than 500 million people are estimated to have genital herpes \nsimplex virus (HSV) infection (13, 14). An estimated 5–25% of people living with HIV worldwide \nalso have chronic hepatitis B and/or hepatitis C infections. The need to better integrate, \nscreen and treat infections related to HIV is critical to improve health outco",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes the large global burden of STIs, HPV, herpes and hepatitis B and C among people with HIV, and the overlap in transmission routes and services. It explains that the guidelines integrate these infections, along with TB and cervical cancer, into person-centred HIV monitoring through suggested minimum datasets and indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data considerations for key populations",
      "pageStart": 36,
      "pageEnd": 38,
      "target": "../sections/sec-011-114-data-considerations-for-key-populations.md",
      "narrative": null,
      "content": "Five key populations are disproportionately affected by HIV and in almost every setting have a \nhigher prevalence and incidence than people outside of these groups (1). These key populations \nare men who have sex with men, sex workers, people who inject drugs, trans and gender \ndiverse people, and people in prisons and other closed settings. Members of these populations \nare also disproportionally affected by viral hepatitis and STIs, and there is increasing \nacknowledgement of the importance of addressing all three infectious disease areas in an \nintegrated, community-led and person-centred m",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies five key populations disproportionately affected by HIV, viral hepatitis and STIs and the social, legal and structural barriers they face. It discusses the risks of recording key population status in routine data and advises against collecting such information where it could harm individuals or deter them from services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p038",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 38,
      "pageEnd": 38,
      "target": "../figures/vfig-p038.webp",
      "narrative": "draft",
      "content": "Fig. 1.2, a block diagram of an integrated data system architecture. A central 'Routine health service data' box shows service sources (HIV prevention, testing, treatment services; STI, TB, hepatitis, cervical cancer services; laboratory; private sector health services; HIV case surveillance; community-based or outreach services; drug and logistics management; civil registration & vital statistics) feeding a minimum dataset, which feeds priority indicators based on individual-level data. These, together with 'Other data sources' (population-based survey statistics, modelled estimates, epidemiologic studies and research, community-led monitoring), flow to 'Data use for programme monitoring & management', which loops to 'Improved health services' and back to the routine data.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strengthening the use of data from other sources",
      "pageStart": 38,
      "pageEnd": 40,
      "target": "../sections/sec-012-115-strengthening-the-use-of-data-from-other-sou.md",
      "narrative": null,
      "content": "For sustainability, the strategic information system of the health sector response to HIV must \nalign with the broader health information system (HIS) as part of an integrated architecture \n(Fig. 1.2). Guidance for national HIS standards and tools are available to support development \nof appropriate HIS and digital health policies, guidelines, strategic plans and roadmaps, \nincluding for system interoperability (see Chapter 6).\nFig. 1.2 Integrated data system architecture \nPopulation-based \nsurvey statistics\nMinimum dataset\nPriority Indicators based on\nindividual-level data\nData use for progra",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that HIV strategic information should fit within the wider health information system, illustrated by an integrated data architecture figure. It notes that routine data cover only people reached by services and should be triangulated with surveys, models and studies, and highlights community-based services and community-led monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What’s new in this consolidation of WHO strategic information guidelines",
      "pageStart": 40,
      "pageEnd": 41,
      "target": "../sections/sec-013-12-whats-new-in-this-consolidation-of-who-strate.md",
      "narrative": null,
      "content": "information guidelines\nThe aim of this consolidation of strategic information guidelines is to provide in one place \nthe recommended data elements, indicators and guidance on data systems and use across \nthe spectrum of health sector HIV services and to reference technical guidelines published \nby WHO and its partners that detail recommended interventions and how to operationalize \nthe collection and use of related strategic information. WHO and the Joint United Nations \nProgramme on HIV/AIDS (UNAIDS) collect information about the uptake of strategic \ninformation recommendations including pati",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the consolidated guidelines bring together data elements, indicators and data-system guidance across all HIV services, replacing two earlier WHO strategic information guidelines from 2017 and 2020. It describes implementation gaps in patient monitoring and case surveillance and the aim of linking individual-level and aggregate data under the collect-once-use-many principle. A box lists new areas, including the first minimum datasets for HIV prevention, STIs, viral hepatitis and cervical cancer.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data system maturity for use of person-centred data",
      "pageStart": 41,
      "pageEnd": 42,
      "target": "../sections/sec-014-121-data-system-maturity-for-use-of-person-centr.md",
      "narrative": null,
      "content": "While these 2022 guidelines focus on the collection, analysis and use of person-centred data \nat the facility, subnational or national level, in many places fully integrated systems are not yet \noperational. These guidelines contain information pertinent to all contexts. In settings where \nperson-centred electronic data systems are not yet mature or at scale, priority indicators that \nare proportions can still be calculated with existing reporting practices to monitor programmes. \nIn other settings, or within individual programmes, electronic person-centred data may be used \nfor facility-level",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that while the guidelines focus on person-centred data, many settings lack mature integrated systems, so priority indicators can still be calculated with existing reporting. It explains how data from digital and paper systems can be combined during transition, with limits on deduplication, and the role of the guidance in common understanding among managers and developers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Objectives and guiding principles",
      "pageStart": 42,
      "pageEnd": 43,
      "target": "../sections/sec-015-13-objectives-and-guiding-principles.md",
      "narrative": null,
      "content": "The overarching goal of these guidelines is to support countries in generating responsive \nperson-centred data from routine national health information management systems. Keeping \nthe person at the centre and understanding how people access services can improve health \ndecision-making and health outcomes. These guidelines aim to strengthen the analysis and \nuse of data at each stage of the cascade and to emphasize person-centred HIV prevention, \ntesting and treatment, integration of HIV-related infections, the use of routine surveillance \ndata to measure impact, and the development and use of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the goal of helping countries generate person-centred data from routine health information systems and use it across the HIV cascade. It lists objectives, such as greater use of individual-level data linked by unique identifiers, and guiding principles including privacy, security, ethics, equity and governance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Process of development",
      "pageStart": 43,
      "pageEnd": 44,
      "target": "../sections/sec-016-14-process-of-development.md",
      "narrative": null,
      "content": "WHO staff and consultants developed these guidelines based on review of recent global and \nregional guidance documents, consultative meetings and inputs of technical experts. The \nminimum datasets and priority indicators included in these guidelines were identified through \nconsultation with technical experts with country-level, regional and global perspectives. \nThe Core Advisory Group, which had responsibility for oversight of guidelines development, \nincluded two co-chairs and members with expertise in strategic information and monitoring \nand evaluation (M&E), with additional representatio",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how WHO developed the guidelines through review of existing guidance, expert consultation, a Core Advisory Group and technical working groups for each programme area. It notes that external contributors completed declarations of interests.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Organization of the guidelines",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../sections/sec-017-15-organization-of-the-guidelines.md",
      "narrative": null,
      "content": "These guidelines are organized into six technical chapters on person-centred HIV prevention \nmonitoring; person-centred HIV patient monitoring for testing, early diagnosis, and treatment; \nintegrating related infections into HIV surveillance systems; harnessing the strength of routine \ndata for HIV surveillance; digital health data; and strengthening data use. Each chapter \nincludes a brief description of critical measurement issues, reasons for selecting the data \nelements included in the minimum dataset and priority indicators for that programme area. \nEach chapter also includes references t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines the six technical chapters of the guidelines, the indicator metadata in Chapter 8, and web annexes containing the full minimum dataset and additional indicators and tools.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Intended audiences",
      "pageStart": 44,
      "pageEnd": 45,
      "target": "../sections/sec-018-16-intended-audiences.md",
      "narrative": null,
      "content": "This guideline is intended primarily for national and subnational HIV programme managers, \nsurveillance officers, partners and other stakeholders involved in the design and use of \nM&E systems, surveillance and tools for the collection, analysis and use of HIV health sector \ndata. These include national-level staff establishing strategic information policy, guidelines, \nframeworks, tools and HIS as well as staff involved with national, subnational and service \ndelivery (facility and community) level collection, analysis and use of HIV-related data to \nmonitor and improve programmes. The guidel",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the intended users of the guidelines, chiefly national and subnational HIV programme managers, surveillance officers and partners, as well as NGOs, private providers and academics.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 45,
      "pageEnd": 49,
      "target": "../sections/sec-019-references.md",
      "narrative": null,
      "content": "1.\t Global AIDS Update 2021. Confronting inequalities: lessons for pandemic responses from \n40 years of AIDS. Geneva: United Nations Joint Programme on HIV/AIDS (UNAIDS); 2021 \n(https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, accessed \n23 June 2022).\n2.\t Justman JE, Mugurungi O, El-Sadr WM. HIV population surveys - bringing precision to the \nglobal response. N Engl J Med. 2018;378:1859-61. doi: 10.1056/NEJMp1801934\n3.\t Grabowski MK, Serwadda DM, Gray RH, Nakigozi G, Kigozi G, Kagaayi J et al. HIV \nprevention efforts and incidence of HIV in Uganda. N Engl J Med. 2017",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the introduction chapter, citing UNAIDS global AIDS updates, population survey and incidence studies, and WHO guidance on strategic information and digital health.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 2 – Person-centred HIV prevention monitoring",
      "pageStart": 49,
      "pageEnd": 50,
      "target": "../sections/sec-020-chapter-2-person-centred-hiv-prevention-monitori.md",
      "narrative": null,
      "content": "PERSON-CENTRED HIV \nPREVENTION MONITORING\n2\nKey recommendations\b\n20\n2.1\t Introduction\b\n21\n2.1.1 Epidemiology of HIV and prevention need \b\n21\n2.1.2 Strategic information for HIV prevention \b\n22\n2.1.3 HIV prevention interventions\b\n24\n2.2\t Individual-level HIV prevention data\b\n26\n2.2.1 Using routine programme data to measure HIV prevention interventions\b\n26\n2.2.2 Anonymity, confidentiality and the use of unique identification (UID) codes \b\n27\n2.2.3 Prioritizing HIV prevention services\b\n28\n2.2.4 Understanding person-centred HIV prevention need \b\n29\n2.2.5 Capturing information on HIV prevention dem",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The contents listing for Chapter 2 on person-centred HIV prevention monitoring, covering prevention epidemiology, individual-level prevention data, confidentiality and unique identifiers, minimum datasets, data use and indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key recommendations",
      "pageStart": 50,
      "pageEnd": 51,
      "target": "../sections/sec-021-key-recommendations.md",
      "narrative": null,
      "content": "NEW   \u00071. \u0007The collection of a minimum dataset of individual-level data elements \non HIV prevention interventions is recommended to measure interventions \nreceived and health outcomes among individuals seeking HIV prevention. \nNEW   \u00072. \u0007Individual-level data on HIV prevention should be used, alongside other \navailable data sources, to strengthen the measurement of: \n\na) the coverage of interventions provided to populations affected by HIV, to \nincreasingly measure individual people reached rather than services delivered \n\nb) prevention impact through longitudinal assessment of HIV status at t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out new key recommendations for HIV prevention monitoring: collecting a minimum individual-level dataset, using it to measure people reached and prevention impact, and recording clinical and behavioural risk factors to target services. It stresses safeguarding confidentiality when linking prevention data to other clinical datasets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p051",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 51,
      "pageEnd": 51,
      "target": "../figures/vfig-p051.webp",
      "narrative": "draft",
      "content": "Fig. 2.1, three donut charts showing the distribution of new HIV infections by population in 2020 for Global, Sub-Saharan Africa and Rest of world. Categories are sex workers, people who inject drugs, men who have sex with men, trans and gender diverse people, clients of sex workers and sex partners of all key populations, and remaining population. The remaining population accounts for 30% globally and 49% in sub-Saharan Africa but 6% in the rest of the world, where men who have sex with men make up 41%. Source: UNAIDS special analysis and epidemiological estimates, 2022.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 51,
      "pageEnd": 51,
      "target": "../sections/sec-022-21-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Epidemiology of HIV and prevention need",
      "pageStart": 51,
      "pageEnd": 52,
      "target": "../sections/sec-023-211-epidemiology-of-hiv-and-prevention-need.md",
      "narrative": null,
      "content": "The prevention of new HIV infections remains critical to achieving the goal to end the HIV \nepidemic by 2030, as set out in the 2016 United Nations Political Declaration (1). Yet, declines \nin HIV incidence have been slow, far short of the global target of reducing annual new HIV \ninfections to under 370 000 by 2025 (2-4). In 2020, 1.5 million (1.0 million–2.0 million) people \nbecame newly infected with HIV, with women and girls accounting for half of all new infections \nglobally and 63% in sub-Saharan Africa (4). While the overall incidence of new infections \nhas been declining since the peak",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes slow declines in HIV incidence, with 1.5 million new infections in 2020, and the rising share among key populations and their partners. It notes that criminalization, stigma and discrimination create barriers that must be addressed for equitable access to prevention.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strategic information for HIV prevention",
      "pageStart": 52,
      "pageEnd": 54,
      "target": "../sections/sec-024-212-strategic-information-for-hiv-prevention.md",
      "narrative": null,
      "content": "Measuring HIV prevention programmes against health outcomes (such as individuals remaining \nHIV-negative or new HIV infections) can be challenging. This is because, by its very nature, HIV \nprevention can be started and stopped at will according to an individual’s need. Therefore, as \nwith all other areas of the HIV response, data from multiple sources are necessary to obtain a \nfull picture of HIV prevention service availability, access and coverage. These sources include \nsurveillance data from population-based surveys (15), bio-behavioural surveys of different key \npopulations (16, 17) and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why HIV prevention outcomes are hard to measure, since people start and stop prevention as needs change, and why multiple data sources are needed. The guidelines focus on routine programmatic data, which can also identify people at elevated risk and track whether interventions are received and used.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV prevention interventions",
      "pageStart": 54,
      "pageEnd": 56,
      "target": "../sections/sec-025-213-hiv-prevention-interventions.md",
      "narrative": null,
      "content": "A person-centred approach should address the range of HIV prevention and other health \nneeds that individuals might have and make appropriate interventions available in a manner \nacceptable to them. The design of HIV prevention programmes should be informed by the local \ncontext and the nature of the local HIV epidemic and tailored to meet the HIV prevention needs \nof the individuals and communities they serve. \nTo meet users’ needs, HIV prevention interventions can be provided in a variety of settings \nand by a range of service providers, including primary, secondary and tertiary health facil",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advocates a person-centred, context-specific approach to HIV prevention delivered through varied settings, including community-led services, in line with the Global AIDS Strategy. It lists evidence-based biomedical and health-sector prevention interventions, from ART and PrEP to needle–syringe programmes and male circumcision, and notes that counselling alone has not shown an effect on incidence. It points to tools for setting prevention targets for key populations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Individual-level HIV prevention data",
      "pageStart": 56,
      "pageEnd": 56,
      "target": "../sections/sec-026-22-individual-level-hiv-prevention-data.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Using routine programme data to measure HIV prevention interventions",
      "pageStart": 56,
      "pageEnd": 57,
      "target": "../sections/sec-027-221-using-routine-programme-data-to-measure-hiv.md",
      "narrative": null,
      "content": "interventions\nIndividual-level data on people living with HIV across HIV treatment and care has proved \ncritical to understanding the effectiveness of HIV treatment at the individual and population \nlevels and has enabled the construction of HIV treatment cascades (24). By comparison, \ncollection and use of individual-level data on HIV-negative people to monitor HIV prevention \nservices and to develop “HIV prevention cascades” has been more limited (30, 31). \nIndividual-level data on HIV prevention can be used to observe a range of factors affecting the \naccessibility and coverage of intervent",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that individual-level data have been central to HIV treatment cascades but little used for prevention, and lists prevention outcomes worth monitoring. It sets out the prerequisites for such data, including confidentiality, standardized tools and a minimum dataset.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Anonymity, confidentiality and the use of unique identification (UID) codes",
      "pageStart": 57,
      "pageEnd": 58,
      "target": "../sections/sec-028-222-anonymity-confidentiality-and-the-use-of-uni.md",
      "narrative": null,
      "content": "(UID) codes \nMaintaining the confidentiality of individual-level health information is important for all \npeople and particularly for populations who may experience criminalization, stigma and \ndiscrimination, such as key populations and adolescents. In many settings same-gender \nsexual activity, sex work, or drug use or possession are stigmatized and, in some settings, \ncriminalized. Health services collecting personally identifying information from clients linked \nto these behaviours raises the potential for negative consequences both for individuals and \nfor service providers and can discou",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why confidentiality of individual-level data matters for key populations and adolescents whose behaviours may be criminalized, listing harms such as law enforcement use and underreporting of risk. It discusses the use of unique identification codes to link records while protecting anonymity, with further guidance in Chapter 6.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Prioritizing HIV prevention services",
      "pageStart": 58,
      "pageEnd": 59,
      "target": "../sections/sec-029-223-prioritizing-hiv-prevention-services.md",
      "narrative": null,
      "content": "It is important that HIV prevention programmes and service providers understand the different \nvulnerabilities and risks of HIV acquisition of the individuals and communities they serve as \nwell as their values and preferences. It is critical to consider how the intersection of society’s \nattitudes toward people based on factors such as their age, gender, ethnicity, disability and \nthe criminalization of key populations leads to greater risk of HIV acquisition and may limit the \navailability and accessibility of HIV prevention interventions. \nA number of different factors can influence whether",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses how intersecting factors such as age, gender and criminalization shape HIV risk and access to prevention, and how individual risk changes over time. It suggests building a process into health information systems to identify people most likely to benefit from prevention services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Understanding person-centred HIV prevention need",
      "pageStart": 59,
      "pageEnd": 62,
      "target": "../sections/sec-030-224-understanding-person-centred-hiv-prevention.md",
      "narrative": null,
      "content": "Conversations between service providers and clients during a consultation are key to \nunderstanding an individual’s HIV prevention needs. Such conversations may take place before \nor after HIV testing, during a sexual health consultation, or when providing HIV prevention \nservices. It should be noted that discussing issues such as sexual behaviours, sexual identity \nand expression, and drug use can be uncomfortable for both client and provider, especially \nwhen these behaviours are stigmatized or criminalized. Providing privacy and confidentiality \nare key; community-led services and peer work",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how client–provider conversations, held with privacy and often with peer support, help identify an individual's HIV prevention needs, and stresses offering prevention to anyone who asks without requiring explanation. It covers the use of prevention prioritization or risk assessment tools when people underestimate their risk, especially adolescents. It advises reassessing need regularly and gives example screening questions to adapt locally.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Capturing information on HIV prevention demand in a health data system",
      "pageStart": 62,
      "pageEnd": 64,
      "target": "../sections/sec-031-225-capturing-information-on-hiv-prevention-dema.md",
      "narrative": null,
      "content": "data system\nThe collection of individual-level data on HIV prevention need allows for the monitoring of \nhow well HIV prevention services are meeting this demand. \nThere are two main sources of data indicating HIV prevention need captured by health data \nsystems: \n1.\t \tData from HIV prevention prioritization questions or information gathered in the \ncourse of providing services can be recorded directly in HIV prevention data systems \nto document differential risk, where this is possible, appropriate and safe to do so. This \ninformation can also indicate that an individual is a man who has sex",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains in WHO's consolidated guidelines on person-centred HIV strategic information how health data systems can capture HIV prevention need, through prioritization questions recorded during services and through records showing an individual has received services for key populations or other at-risk groups. It warns that people may not answer behavioural questions, so recorded need may be underestimated. It notes that trans and gender diverse people can be identified from data on sex assigned at birth and current gender identity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Entry points to the data system for the collection of individual-level prevention data",
      "pageStart": 64,
      "pageEnd": 64,
      "target": "../sections/sec-032-226-entry-points-to-the-data-system-for-the-coll.md",
      "narrative": null,
      "content": "level prevention data \nEntry or referral to HIV prevention interventions can come from a number of prevention \nand allied programmes in whatever setting the intervention is provided, such as a facility, \noutpatient clinics, community settings and outreach. Individual-level data may be recorded at \nthe referral or entry point where the HIV prevention intervention is provided. Various potential \nentry points are listed in Box 2.5. \nBox 2.5 Potential entry points for providing HIV prevention \ninterventions \n•\t HIV testing\n•\t STI services\n•\t PrEP services\n•\t PEP services\n•\t VMMC\n•\t various service",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the many entry points where individual-level HIV prevention data can be recorded, such as HIV testing, STI, PrEP and PEP services, harm reduction, gender-based violence, family planning, antenatal care and youth programmes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Registration process",
      "pageStart": 64,
      "pageEnd": 65,
      "target": "../sections/sec-033-227-registration-process.md",
      "narrative": null,
      "content": "Data systems collecting individual-level data on HIV prevention will need to collect basic \ndemographic information on each individual and to assign some form of unique identification \nso that individuals can be followed longitudinally. Since collecting personally identifying \ninformation is not advisable when providing HIV prevention interventions, an anonymous \nUID code can be issued at the time of registration (see section 2.2.2). In some circumstances, \nhowever, it may be appropriate or necessary to record contact details for the purposes of \nfollow-up or access to telemedicine services. T",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes registration in HIV prevention data systems, recommending an anonymous unique identifier rather than personal details, with contact information recorded only with informed consent and strong confidentiality safeguards. It lists the registration data to collect and suggests recording both current gender and sex assigned at birth where appropriate.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "A minimum dataset for HIV prevention",
      "pageStart": 65,
      "pageEnd": 66,
      "target": "../sections/sec-034-228-a-minimum-dataset-for-hiv-prevention.md",
      "narrative": null,
      "content": "In the course of delivering each HIV prevention intervention, collection of a minimum set of \nindividual-level data is suggested (Table 2.2). In this minimum dataset, the date that an event \noccurs (for example, date of HIV test, date PrEP prescribed, etc.) serves to indicate that the \nevent occurred as well as when it occurred. These data can be collected at the point where \nan HIV prevention intervention is provided. Standardized paper forms, electronic systems or \nmobile devices such as a phone or tablet can be used to record the data. A comprehensive \nminimum dataset for all programme area",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends collecting a minimum set of individual-level data for each HIV prevention intervention, using event dates to show what happened and when, on paper or electronic tools. A table sets out the minimum dataset for interventions such as HIV testing, condoms, PrEP, needle–syringe programmes, opioid agonist maintenance treatment and voluntary medical male circumcision.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of individual-level data on HIV prevention",
      "pageStart": 66,
      "pageEnd": 66,
      "target": "../sections/sec-035-23-use-of-individual-level-data-on-hiv-preventio.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of individual-level HIV prevention data for client management",
      "pageStart": 66,
      "pageEnd": 67,
      "target": "../sections/sec-036-231-use-of-individual-level-hiv-prevention-data.md",
      "narrative": null,
      "content": "management\nHealth care providers can use individual-level HIV prevention data to improve the personalized \nmanagement of a person’s prevention needs. Follow-up actions relevant to different \ninterventions can be flagged by regularly reviewing data records or through alerts generated \nby an automated system. If an individual has not attained a relevant outcome (for example, \nthey have missed an appointment or not received a service when due), they can be followed up \nand provided with this missed services. Reminders can be issued in person or through phone \ncalls, text messages, email or social",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how providers can use individual prevention records and automated alerts to follow up people who miss appointments or services, with reminders sent only with consent. It stresses protecting privacy when contacting people and referring them to other needed services such as STI or hepatitis care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of individual-level data for programme management",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../sections/sec-037-232-use-of-individual-level-data-for-programme-m.md",
      "narrative": null,
      "content": "Providers can use individual-level data aggregated at the level of the site or facility to monitor \nservice utilization and outcomes among the clients accessing the service.\nThis information can be used to improve service delivery by: \na)\t monitoring service utilization and delivery\nb)\t evaluating service delivery by monitoring intervention outcomes \nc)\t ensuring that commodities are appropriately stocked\nd)\t identifying individuals and groups that may benefit from HIV prevention interventions\ne)\t monitoring rates of follow-up for different interventions\nf)\t monitoring referrals made and succe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how site-level aggregation of individual data can help monitor service use, outcomes, stock levels, follow-up and referrals, with automatic reporting through tools such as DHIS2 and dashboards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Longitudinal individual-level data as the basis for routine aggregated reporting",
      "pageStart": 67,
      "pageEnd": 68,
      "target": "../sections/sec-038-233-longitudinal-individual-level-data-as-the-ba.md",
      "narrative": null,
      "content": "aggregated reporting\nIndicators derived from aggregated routinely collected individual-level data can provide \nimportant information on trends, programmatic gaps and various other aspects of HIV \nprevention programme delivery, which previously required research or surveys to obtain – \nfor example, whether individuals continue to face elevated risk, which prevention methods \nthey choose, the presence of related infections and whether they remain HIV-negative. HIV \nprevention indicators can be derived to examine the extent to which an intervention is reaching \nthose who would benefit from it and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that indicators derived from routine individual-level data can reveal trends and programme gaps that once needed surveys, such as ongoing risk, prevention choices and whether people stay HIV-negative. It describes tracking unique individuals and commodity volumes and cohort-style analysis, and notes the importance of monitoring community-led services against Global AIDS Strategy targets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of individual-level data to construct HIV prevention cascades",
      "pageStart": 68,
      "pageEnd": 69,
      "target": "../sections/sec-039-234-use-of-individual-level-data-to-construct-hi.md",
      "narrative": null,
      "content": "cascades\nWhile HIV treatment cascades can be derived across the continuum of care from initial HIV \ndiagnosis to receiving ART and achieving viral suppression, construction of HIV prevention \ncascades is more complicated due to a number of factors:\na)\t HIV prevention interventions are delivered in a variety of ways (at a single point in time, \nepisodically or continuously) (9, 10). \nb)\t An individual’s level of HIV risk and, therefore, the total population exposed to elevated \nrisk change over time.\nc)\t Relevant outcomes vary and, for some prevention interventions, do not reflect a linear \npro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why HIV prevention cascades are harder to build than treatment cascades, since interventions are delivered in varied ways, risk changes over time, outcomes are non-linear and commodities come from many sources. It points to existing frameworks, including a PAHO approach for key populations, and advises reading prevention cascades alongside testing and treatment cascades.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV prevention indicators",
      "pageStart": 69,
      "pageEnd": 74,
      "target": "../sections/sec-040-24-hiv-prevention-indicators.md",
      "narrative": null,
      "content": "Priority indicators for HIV prevention are listed in Table 2.3; additional indicators are listed in \nWeb Annex B. These indicators use data from a range of sources, including individual-level \nprogramme data, programme data that are not linked to individuals using some form of unique \nidentification but are reported in aggregate form, and survey data.\nThe recommended priority and additional indicators that utilize individual-level data draw on \nelements from the minimum dataset listed in Table 2.2. While countries are in transition to \nHIS that collect individual-level data electronically, the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the priority indicators for HIV prevention, drawing on individual-level programme data, aggregate data and surveys, with disaggregation by key population and other factors. A table defines each indicator with numerators and denominators, covering condom distribution and use, PrEP recipients, coverage and volume, and other prevention services. It ends with indicators on retesting among people at elevated risk who previously tested negative.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 74,
      "pageEnd": 79,
      "target": "../sections/sec-041-references.md",
      "narrative": null,
      "content": "1.\t United Nations General Assembly. Political declaration on HIV and AIDS. On the fast track \nto accelerating the fight against HIV and to ending the AIDS epidemic by 2030. New York: \nUnited Nations; 2016 (https://digitallibrary.un.org/record/833243?ln=es, accessed 24 June \n2022).\n2.\t Global AIDS Strategy 2021–2026. End inequalities. End AIDS. Geneva: Joint United Nations \nProgramme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/en/Global-AIDS-\nStrategy-2021-2026, accessed 24 June 2022).\n3.\t Global AIDS Update 2021. Confronting inequalities: lessons for pandemic responses from \n40 years o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the HIV prevention chapter of the strategic information guidelines, citing UN political declarations, UNAIDS strategies and data, WHO guidance and studies on prevention and community-led responses.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 3 – Person-centred HIV patient monitoring for testing, early diagnosis and treatment",
      "pageStart": 79,
      "pageEnd": 82,
      "target": "../sections/sec-042-chapter-3-person-centred-hiv-patient-monitoring.md",
      "narrative": null,
      "content": "PERSON-CENTRED HIV \nPATIENT MONITORING FOR \nTESTING, EARLY DIAGNOSIS \nAND TREATMENT\n3\nKey recommendations\b\n52\n3.1\t Introduction\b\n53\n3.1.1 Purpose of person-centred monitoring of HIV testing, treatment and care \b\n53\n3.1.2 Evolution of person-centred HIV patient monitoring \b\n54\n3.1.3 Application of this guidance \b\n58\n3.2\t HIV testing services, early diagnosis and linkage to treatment\b\n59\n3.2.1 Purposes of monitoring testing \b\n61\n3.3\t Key considerations for monitoring HTS and linkage\b\n63\n3.3.1 Increasing number of people living with HIV who know their status \b\n63\n3.3.2 Early HIV diagnosis\b\n63\n3.3",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The table of contents for Chapter 3 on person-centred HIV patient monitoring for testing, early diagnosis and treatment, listing sections on HIV testing and linkage, ART initiation, retention and viral suppression, data quality and use, and country adaptation and digital transition.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key recommendations",
      "pageStart": 82,
      "pageEnd": 83,
      "target": "../sections/sec-043-key-recommendations.md",
      "narrative": null,
      "content": "NEW        \u00071. \u0007Promote the analysis and use of routinely collected testing data to \noptimize HIV testing services, reaching populations and settings with the \nlargest proportion of people living with HIV who do not know their status \nand supporting early HIV diagnosis. \n\na) \u0007Improve the monitoring of time to HIV diagnosis to support rapid \nART initiation and engagement in care, thus reducing morbidity and \nmortality.\nUPDATE   \u00072. \u0007Use of person-centred patient data is recommended to continuously \nassess interruption of HIV treatment to improve re-engagement \nand retention in care. \n\na) \u0007Stren",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the chapter's key recommendations on HIV patient monitoring, marked as new or updated, including using routine testing data to reach undiagnosed people and support early diagnosis. They also cover using person-centred data to detect treatment interruption and support re-engagement, standardized digital tools, and monitoring differentiated service delivery and its outcomes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 83,
      "pageEnd": 83,
      "target": "../sections/sec-044-31-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Purpose of person-centred monitoring of HIV testing, treatment and care",
      "pageStart": 83,
      "pageEnd": 84,
      "target": "../sections/sec-045-311-purpose-of-person-centred-monitoring-of-hiv.md",
      "narrative": null,
      "content": "treatment and care \nHIV patient monitoring encompasses the routine collection, compilation, analysis and use \nof data on people living with HIV over time and across service delivery points. Its primary \npurposes are to guide the clinical management of people living with HIV and to ensure the \nquality and continuity of HIV testing, early diagnosis and access to treatment and care services. \nPerson-centred monitoring generates data that track the health status of people living with \nHIV over time and support case management, enable tracking of HIV epidemic trends, measure \nprogramme performance",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines HIV patient monitoring as routinely gathering, analysing and using data about people with HIV across services and over time, mainly to guide clinical care and ensure continuity of testing and treatment. It lists further uses of the data, such as tracking epidemic trends, measuring programme performance and informing drug stock management to reduce wastage and stock-outs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p084",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 84,
      "pageEnd": 84,
      "target": "../figures/vfig-p084.webp",
      "narrative": "draft",
      "content": "Fig. 3.1, a chevron diagram of the scope of HIV patient monitoring within the 2022 WHO consolidated HIV strategic information guidelines. Three arrows run in sequence: HIV testing, ART initiation and Viral suppression, above a bar spanning all three labelled 'Linkage to care, retention on ART and integrated chronic care'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evolution of person-centred HIV patient monitoring",
      "pageStart": 84,
      "pageEnd": 88,
      "target": "../sections/sec-046-312-evolution-of-person-centred-hiv-patient-moni.md",
      "narrative": null,
      "content": "The investments that countries have made in digital HIS, including electronic medical records \n(EMRs) and the adoption of UIDs, has strengthened person-centred patient monitoring and \nservice delivery. The quality of individual-level data has also improved over time, not only \nfor patient monitoring but also as the underlying data source for aggregate reporting for \nprogramme management, case surveillance and global monitoring. This has given rise to the \nconcept of a prioritized minimum dataset across all data use cases, which is central to building \nstronger, more efficient and more effectiv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how investments in digital health information systems, electronic medical records and unique identifiers have strengthened person-centred monitoring and led to a prioritized minimum dataset. It explains that the chapter updates WHO's 2017 patient monitoring guidance to cover the full care cascade and support differentiated service delivery. It also notes the expansion from 40 to 80 priority indicators, of which 36 come from patient monitoring and 25 are core, plus optional additional indicators for countries with stronger systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p087",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 87,
      "pageEnd": 87,
      "target": "../figures/vfig-p087.webp",
      "narrative": "draft",
      "content": "Fig. 3.2, a grid overview of the 36 priority, core and differentiated indicators from the HIV patient monitoring system, arranged along the HIV testing, treatment and care cascade (Testing, Linkage to care, ART initiation, Retention in HIV care, VL suppression). Columns list indicator codes such as HTS.1–HTS.6, TBH.1–TBH.4, VER.1–VER.7, ART.1–ART.9 and DSD.1–DSD.5, with the 1st, 2nd and 3rd 95 targets marked at HTS.1, ART.1 and ART.3. A separate lower block lists differentiated priority indicators DFT.1–DFT.5 for high TB–HIV burden countries; shading distinguishes core, priority and differentiated indicators and asterisks mark new 2022 indicators.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Application of this guidance",
      "pageStart": 88,
      "pageEnd": 89,
      "target": "../sections/sec-047-313-application-of-this-guidance.md",
      "narrative": null,
      "content": "The updated guidance in this chapter seeks particularly to support monitoring of people living \nwith HIV as they move between health facilities over time. WHO recommends the use of an HIV \npatient card and ART register or electronic versions of these, which remain at the health facility \nso that the facility retains overall responsibility for patient management and follow-up, with \nprompt and efficient data flow from community settings where HIV testing and ART services \nare delivered. \nAt the facility level, the intention is to facilitate the use of integrated facility-held patient cards, \nfo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the updated guidance supports monitoring people as they move between facilities, recommending facility-held patient cards, ART registers or electronic records with data flowing in from community services, as well as new tools for differentiated service delivery. It describes the intended audiences and notes that pharmacy services and non-HIV TB and maternal and child health data elements are outside its scope.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV testing services, early diagnosis and linkage to treatment",
      "pageStart": 89,
      "pageEnd": 91,
      "target": "../sections/sec-048-32-hiv-testing-services-early-diagnosis-and-link.md",
      "narrative": null,
      "content": "to treatment\nBox 3.2 What’s new in HTS relevant to HIV patient monitoring \nFacility-based testing\n•\t Pregnant women and key populations: All pregnant women should be tested \nfor HIV, syphilis and hepatitis B surface antigen (HBsAg) at least once and as \nearly as possible. In the 2022 WHO Consolidated guidelines for HIV, viral hepatitis \nand STI prevention, diagnosis and treatment and care for key populations, this \nrecommendation was expanded to include key populations. Since 2019 WHO has \nrecommended dual HIV/syphilis rapid diagnostic tests (RDTs) as the first test in HIV \ntesting strategies",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A box summarizing new WHO HIV testing recommendations relevant to patient monitoring, including testing all pregnant women for HIV, syphilis and hepatitis B, dual HIV/syphilis rapid tests in antenatal care and differing approaches for high- and low-burden settings. It also covers self-testing, index and network-based testing and the need to update tools and records to track linkage between facilities and community services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Purposes of monitoring testing",
      "pageStart": 91,
      "pageEnd": 93,
      "target": "../sections/sec-049-321-purposes-of-monitoring-testing.md",
      "narrative": null,
      "content": "Understanding HIV testing history, patterns of testing, retesting and test results is necessary to \nguide the provision of support and clinical care to clients. Patient monitoring systems, whether \npaper-based or electronic, can facilitate effective clinical management and also generate data \nfor programme monitoring. To support \ncollection of comprehensive client data and \nsupport linkage, HIV programmes should \npromote person-centred HIV patient \nmonitoring that includes all feasible and \nappropriate prevention, HTS and ART service \ndelivery points.\nIn the context of the WHO HIV testing reco",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that understanding people's HIV testing history and results guides their care and that monitoring should cover all prevention, testing and treatment service points. It outlines the purposes of testing data, such as optimizing case finding and linkage to ART and prevention, and presents a table of six priority HIV testing indicators. It ends with guidance on which partners and family members of index clients should be offered testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key considerations for monitoring HTS and linkage",
      "pageStart": 93,
      "pageEnd": 93,
      "target": "../sections/sec-050-33-key-considerations-for-monitoring-hts-and-lin.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Increasing number of people living with HIV who know their status",
      "pageStart": 93,
      "pageEnd": 93,
      "target": "../sections/sec-051-331-increasing-number-of-people-living-with-hiv.md",
      "narrative": null,
      "content": "status \nAs HIV testing and treatment expands, there is a greater need to focus testing services so \nas to reach individuals most at risk of acquiring HIV and to support access to HIV prevention \nand treatment services, in the process achieving the first 95 (testing) target. However, as the \nproportion of people living with HIV who are aware of their HIV serologic status increases, \nthe testing yield (the percentage testing positive) diminishes, and reaching at-risk populations \nbecomes more challenging. The analysis and use of routine testing data are critical to selecting \nand optimizing impl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that as more people living with HIV know their status, test positivity falls and reaching undiagnosed people becomes harder, making analysis of routine testing data essential. It explains how unique identifiers enable tracking along the care continuum and introduces indicators on test volume and positivity and on individuals testing positive.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Early HIV diagnosis",
      "pageStart": 93,
      "pageEnd": 94,
      "target": "../sections/sec-052-332-early-hiv-diagnosis.md",
      "narrative": null,
      "content": "Early diagnosis is key to treatment success, improved patient outcomes and reduced onward \nHIV transmission. New diagnoses likely reflect a mix of those newly identified with HIV \ninfection, those previously diagnosed but not linked to care and those previously diagnosed but \ndisengaged from HIV treatment and care services. Monitoring CD4 count and disease stage at \ndiagnosis is important to identify late diagnoses, as well as people with advanced HIV disease, \nfor effective management.\nEarly diagnosis enables early linkage to care and rapid ART initiation. Expanding testing \nservices outside",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Highlights early diagnosis as key to treatment success and reduced transmission, recommending monitoring of CD4 count and disease stage at diagnosis to detect late presenters. It stresses self-testing and community and network-based testing with timely linkage, supported by interoperable data systems and community-led monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-053",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Linkage to treatment and care",
      "pageStart": 94,
      "pageEnd": 96,
      "target": "../sections/sec-053-333-linkage-to-treatment-and-care.md",
      "narrative": null,
      "content": "Linkage to treatment and care is the first step toward onward services, including timely \ninitiation of ART as well as access to interventions to prevent the further transmission of HIV, \nto prevent other infections and to manage co-morbidities. Linkage to treatment and care is \nessential to achieve programmatic impact and effective patient management and care. Delays \nin ART linkage are associated with lower levels of viral suppression, higher likelihood of viral \nresistance and increased HIV morbidity, mortality and transmission rates (5-8). \nImproving data use, together with the use of UIDs",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that prompt linkage to treatment improves viral suppression and reduces resistance, illness, death and transmission, and that it includes re-engaging people who have dropped out of care. It describes the core linkage indicator measuring the share of newly diagnosed people who start ART, disaggregated by time since diagnosis. It also covers partner and contact testing services with consent and confidentiality, their cascade data, and a survey-based indicator on key populations who know their status.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-054",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Standardized data collection tools for HTS",
      "pageStart": 96,
      "pageEnd": 97,
      "target": "../sections/sec-054-334-standardized-data-collection-tools-for-hts.md",
      "narrative": null,
      "content": "Annexes provide examples of countries’ standardized data collection tools for HTS. These \ninclude an HTS register (Web Annex C), digital scan forms that include an HTS initial screening \nregister (Web Annex F), an HTS confirmatory register (Web Annex E) and an HIVST distribution \nregister (Web Annex D) from Malawi.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that the annexes include examples of standardized HIV testing data collection tools from Malawi, such as testing, screening, confirmatory and self-test distribution registers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-055",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Minimum dataset",
      "pageStart": 97,
      "pageEnd": 97,
      "target": "../sections/sec-055-335-minimum-dataset.md",
      "narrative": null,
      "content": "Data collection practices and completeness of records may vary across settings and testing \napproaches. Where possible, HIV testing information should be collected in a standardized \nmanner across all service sites, including at the facility and community levels. At a minimum \nthe following information should be recorded: \n•\t HIV test date \n•\t HIV test result \n•\t date of diagnosis \n•\t date that client received the result \n•\t linkage to care, where feasible and appropriate.\nFor details see Web Annex A. Minimum dataset for HIV testing, which includes the above data \nelements for HTS.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the minimum HIV testing data to record consistently across facility and community sites: test date, result, date of diagnosis, date the result was received and linkage to care where feasible.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-056",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ART initiation, retention and viral suppression",
      "pageStart": 97,
      "pageEnd": 98,
      "target": "../sections/sec-056-34-art-initiation-retention-and-viral-suppressio.md",
      "narrative": null,
      "content": "Box 3.3 What’s new in HIV treatment relevant to HIV patient \nmonitoring \n•\t Rapid initiation and same-day start of ART: Since 2017 WHO has recommended \nthat ART should be offered to all people living with HIV following a confirmed HIV \ndiagnosis and clinical assessment within seven days of diagnosis and preferably on \nthe same day as confirmed HIV diagnosis, for people who are ready to start ART \n(11). Patient monitoring tools and, where in use, EMR systems should be updated to \nmonitor rapid treatment initiation. \n•\t Updates to WHO recommendations for preferred and alternative first-, \nsecond",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A box summarizing new WHO HIV treatment recommendations relevant to patient monitoring, such as rapid and same-day ART initiation, updated first-, second- and third-line regimens and a revised viral load monitoring algorithm. It notes that patient tools, electronic records and the minimum dataset must be updated accordingly, including for revised antiretroviral toxicity indicators covering weight gain, cardiometabolic effects and adverse pregnancy outcomes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-057",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What to monitor and relevant treatment indicators",
      "pageStart": 98,
      "pageEnd": 102,
      "target": "../sections/sec-057-341-what-to-monitor-and-relevant-treatment-indic.md",
      "narrative": null,
      "content": "In the context of current WHO “treat all” recommendations, it remains critical to monitor \npeople living with HIV who receive ART over time as they move between health facilities and \naccess care at different service delivery points. Priority indicators for HIV treatment focus on \nmonitoring the treatment cascade from ART initiation and/or re-entry into treatment through \nto treatment outcomes that include retention, VL suppression, treatment discontinuation, ARV \ntoxicity, LTFU and death (1) (see Table 3.2 and Chapter 8). \nAll the indicators shown in Table 3.2 are drawn from the HIV patient m",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that under WHO's treat-all policy, people on ART must be monitored over time as they move between facilities, with priority treatment indicators tracking the cascade from initiation or re-entry to retention, viral suppression, discontinuation, toxicity, loss to follow-up and death. It presents a table of these indicators, starting with ART coverage towards the second 95 target and total attrition. It describes updates to the attrition indicator and invites country feedback on its feasibility.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-058",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring ART initiation, late initiation and clinical management",
      "pageStart": 102,
      "pageEnd": 104,
      "target": "../sections/sec-058-342-monitoring-art-initiation-late-initiation-an.md",
      "narrative": null,
      "content": "management \nART initiation should follow the overarching principles of providing person-centred care. \nPerson-centred care should be focused and organized around the health needs, preferences \nand expectations of people and communities. Likewise, patient monitoring should also be \nperson-centred and enable longitudinal monitoring of people living with HIV as they access HIV \ntreatment and care services and, where relevant, re-engage in care and reinitiate treatment. \nART initiation is captured by the indicators ART.4. New ART patients and ART.5. Late ARV \ninitiation.\nSince 2017 WHO has recomme",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses person-centred ART initiation and introduces the indicators on new ART patients and late initiation, with a table of WHO recommendations on when to start ART, including rapid and same-day initiation and exceptions. It covers monitoring of clinical management and lists paediatric monitoring priorities such as early infant diagnosis coverage and age at diagnosis and treatment start. It also notes the need for fine age disaggregation of testing and treatment indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-059",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring treatment outcomes",
      "pageStart": 104,
      "pageEnd": 105,
      "target": "../sections/sec-059-343-monitoring-treatment-outcomes.md",
      "narrative": null,
      "content": "Viral suppression \nA number of updates have been made to the treatment monitoring algorithm. First, the initial \nVL test should be collected and tested, and the result should be reviewed, by the time of the \nsix-month visit after ART initiation. The timing of subsequent VL monitoring tests remains \nthe same (12 months after ART initiation and yearly thereafter). Second, for patients with \nan unsuppressed VL, a second VL test should be performed three months after the initial \nelevated VL (measured by indicator ART.8. Appropriate second VL test after adherence \ncounselling), with enhanced adher",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes updates to viral load monitoring, with the first test reviewed by six months after starting ART and a repeat test three months after an unsuppressed result following enhanced adherence counselling. It distinguishes treatment failure above 1,000 copies/mL from lower detectable levels and presents WHO's 2021 viral load testing algorithm with actions for each result.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p105",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 105,
      "pageEnd": 105,
      "target": "../figures/vfig-p105.webp",
      "narrative": "draft",
      "content": "Fig. 3.3, a flowchart of the HIV treatment monitoring algorithm. Routine viral load monitoring (result by 6 months after ART initiation, at 12 months and yearly thereafter) branches into undetectable (maintain ARV drug regimen), suppressed (viral load detected and ≤1000 copies/mL) or unsuppressed (>1000 copies/mL; if on an NNRTI-based regimen, switch). Suppressed and unsuppressed results lead to enhanced adherence counselling and a repeat viral load test after 3 months, after which unsuppressed results lead to switching to an appropriate regimen. Source: WHO, 2021.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-060",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ART retention/attrition",
      "pageStart": 105,
      "pageEnd": 106,
      "target": "../sections/sec-060-344-art-retentionattrition.md",
      "narrative": null,
      "content": "The main function of an ART programme, after initiation, is to support retention in treatment \nand adherence in order to achieve viral suppression and so reduce mortality. Long-term \nretention in care is a key challenge, with impacts on patient health, the emergence of HIV \ndrug resistance and onward transmission of HIV. Programmatic data from sub-Saharan Africa \nindicate that, five years after initiating ART, nearly one fifth (19%) of patients had stopped ART \nand 15–20% had died (13, 14). \n76\nConsolidated guidelines on person-centred HIV strategic information: strengthening routine data for",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that retention on ART is key to viral suppression and lower mortality, citing sub-Saharan African data showing nearly one fifth stopped ART and 15–20% died within five years. It describes monitoring attrition and the role of unique identifiers in tracking people between facilities and avoiding miscounting of silent transfers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-061",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Loss to follow-up",
      "pageStart": 106,
      "pageEnd": 108,
      "target": "../sections/sec-061-345-loss-to-follow-up.md",
      "narrative": null,
      "content": "ART clients moving into out of and among health facilities. In addition, these data should \nbe analysed to identify facilities that need support and the reasons for retention problems, \nincluding health system issues (long waiting times, quality of service), sociodemographic issues \nand client- and treatment-related factors (for example, ARV toxicity). These should be assessed \nand observations used to inform improvements in treatment programmes. \n3.4.5 Loss to follow-up \nLoss to follow-up generally refers to the unknown outcomes of people living with HIV who \nhave not returned to a facility/c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for analysis of attrition data to find facilities needing support and the causes of poor retention, from waiting times to drug toxicity. It explains that people counted as lost to follow-up are often silent transfers, deaths or discontinuations, and describes data-driven tracing and re-engagement, criteria for tracing and an updated patient card recording prior ARV exposure and restarts. It also mentions monitoring ART initiation alongside treatment interruption as people return to care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p107",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 107,
      "pageEnd": 107,
      "target": "../figures/vfig-p107.webp",
      "narrative": "draft",
      "content": "Fig. 3.4, a staircase diagram of the cyclical cascade of HIV care. Four stages rise in steps: Stage 1 HIV+ diagnosis / HIV+ re-diagnosis, Stage 2 linked / relinked to HIV care, Stage 3 initiated / reinitiated on ART, Stage 4 early retention (<6 months), leading to long-term retention (>6 months). At each step a dashed arrow marks disengagement (after positive test, after linkage, within 6 months of ART, after 6 months of ART), and a dotted 're-engagement in care' path loops back to the start. Source: Ehrenkranz et al., 2021.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-062",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Advanced HIV disease",
      "pageStart": 108,
      "pageEnd": 111,
      "target": "../sections/sec-062-346-advanced-hiv-disease.md",
      "narrative": null,
      "content": "Advanced HIV disease in adults and adolescents is defined by a CD4 cell count of less than \n200 cells/mm3 and/or WHO clinical stage 3 or 4 disease (2). All children younger than five years \nof age living with HIV are considered to have advanced HIV disease. People with advanced \nHIV disease are at greater risk of mortality and require closer follow-up during the initial \nperiod of ART to monitor the response to treatment and to identify signs and symptoms of \npossible immune reconstitution inflammatory syndrome and other adverse events. Individuals \nwith advanced HIV disease could be those who",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines advanced HIV disease as a CD4 count below 200 cells/mm³ or WHO clinical stage 3 or 4 in adults and adolescents, and all children under five living with HIV, noting these people need closer follow-up. It describes the package of screening, prophylaxis and rapid ART recommended for advanced disease and the data elements to monitor it. It also stresses resource planning and monitoring for immune reconstitution inflammatory syndrome and adverse drug reactions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-063",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ARV toxicity monitoring",
      "pageStart": 111,
      "pageEnd": 113,
      "target": "../sections/sec-063-347-arv-toxicity-monitoring.md",
      "narrative": null,
      "content": "As ART scale-up continues, with earlier and more prolonged exposure to treatment, and \nwith the transition to new ARVs among all age groups including pregnant and breastfeeding \nwomen, monitoring the safety of ARV drugs has become a critical component of HIV treatment \nand prevention programmes. Newer ARVs have more favourable toxicity profiles and provide \nan opportunity to standardize and optimize HIV treatment. Still, ARV-associated toxicities are \namong the most common reasons reported for ART non-adherence, treatment discontinuation \nor drug substitution. In this context WHO recommends th",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why monitoring ARV drug safety is increasingly important as treatment scales up and newer drugs are introduced, including for pregnant and breastfeeding women. It describes WHO's recommended combination of approaches, such as pregnancy safety surveillance and active and routine toxicity monitoring. A table lists data elements for monitoring weight gain and cardiometabolic toxicity, including risk factors and drug exposure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p113",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 113,
      "pageEnd": 113,
      "target": "../figures/vfig-p113.webp",
      "narrative": "draft",
      "content": "Fig. 3.5, a diagram of longitudinal monitoring of adverse drug reactions and clinical characteristics among people receiving ARV drugs, based on data extraction from electronic medical records. A timeline shows extraction points: first clinical encounter (DTG or new antiretroviral drug initiated), periodic intervals such as 6 months, 12 months, 18 months, and continue periodically. Below, data to be extracted are grouped as weight gain, patient demographic characteristics, medical history and clinical characteristics, comorbidities, risk factors associated with weight gain, and drug exposure. Source: WHO, 2020.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-064",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Early warning indicators of HIV drug resistance",
      "pageStart": 113,
      "pageEnd": 116,
      "target": "../sections/sec-064-348-early-warning-indicators-of-hiv-drug-resista.md",
      "narrative": null,
      "content": "The early warning indicators (EWIs) are a set of standard quality-of-care indicators used \nto assess whether ART programmes deliver services of sufficient quality to minimize the \nemergence of HIV drug resistance. The EWIs use standardized definitions that have evolved \nover time as programmes mature and public health actions are refined (Table 3.5). Monitoring \nEWIs is useful to identify gaps in service delivery that can be corrected at the clinic or \nprogramme level to minimize the risk of resistance as well as to optimize overall programme \nperformance. Findings from EWI monitoring can be u",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes early warning indicators of HIV drug resistance, a set of quality-of-care measures used to identify clinics where service gaps could foster resistance. It reviews viral, drug, patient and programme factors linked to resistance and presents a table of the current indicators and targets. It also describes a WHO tool for collecting and reporting the indicators and urges countries to use routine patient monitoring rather than parallel systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-065",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring considerations for paediatric populations",
      "pageStart": 116,
      "pageEnd": 118,
      "target": "../sections/sec-065-349-monitoring-considerations-for-paediatric-pop.md",
      "narrative": null,
      "content": "Monitoring for children includes general and HIV-specific monitoring. Age disaggregation \n(five-year intervals) is important, as interventions may depend on age. \nKey general child health monitoring includes: \n•\t growth monitoring (weight, height and mid-upper arm circumference measurements)\n•\t developmental assessments to determine achievement of motor, sensory, cognition, \ncommunication, behaviour, social and adaptive skills\n•\t immunizations based on country-specific immunization schedules\n•\t infant feeding practices in the context of HIV. (WHO infant feeding guidelines recommend \nthat mothe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out general child health monitoring for children living with HIV, such as growth, development, immunization and infant feeding, noting WHO guidance that mothers on ART with suppressed viral loads can breastfeed up to two years. It lists additional paediatric indicators, including viral suppression by age, psychosocial support and optimized second-line regimens, and stresses continuity of records as children move into adolescent and adult care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-066",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring vertical transmission",
      "pageStart": 118,
      "pageEnd": 122,
      "target": "../sections/sec-066-35-monitoring-vertical-transmission.md",
      "narrative": null,
      "content": "Box 3.8 What’s new in monitoring vertical transmission? \n•\t A focus on strengthening monitoring of the PMTCT cascade for prevention of \nmother-to-child transmission (PMTCT) across multiple service delivery points and \nextended follow-up to improve tracking throughout the entire exposure period; \n•\t Increased emphasis on elimination of vertical transmission of HIV to reduce new \ninfections in infants/young children as well as improve maternal health; this is \naccompanied by monitoring of HIV vertical transmission that focuses on cascade \noutcomes such as viral suppression (see below) and early",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes what is new in monitoring vertical transmission of HIV, including stronger tracking of the PMTCT cascade across services and over the full exposure period and an emphasis on elimination. It describes the priority indicator on viral suppression at labour and delivery and recent WHO recommendations relevant to pregnant and breastfeeding women. It explains that these changes require updates to patient monitoring tools and indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-067",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Conceptual framework for preventing vertical transmission",
      "pageStart": 122,
      "pageEnd": 123,
      "target": "../sections/sec-067-351-conceptual-framework-for-preventing-vertical.md",
      "narrative": null,
      "content": "Monitoring of PMTCT services needs to follow the cascade across multiple service delivery \npoints and over a prolonged period, for both mother and child' from primary prevention and \naccess to comprehensive sexual and reproductive health services to diagnosing and treating \nHIV-positive mothers and retaining them on ART, ensuring safe delivery and optimizing infant \nfeeding practices to, finally, tracking exposed infants and young children throughout the \nexposure period to ensure early diagnosis and treatment of those who become infected.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines the conceptual framework for monitoring PMTCT across multiple services and over a long period, from primary prevention and reproductive health services to treating mothers and following exposed infants to final diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-068",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Following the cascade across multiple service delivery points and over prolonged periods",
      "pageStart": 123,
      "pageEnd": 123,
      "target": "../sections/sec-068-352-following-the-cascade-across-multiple-servic.md",
      "narrative": null,
      "content": "and over prolonged periods\nTools to collect data must reflect the patient care workflows of these different service delivery \npoints and possibly different health facilities and be able to track mother–baby pairs from one \nsuch point to another. The patient monitoring system for vertical transmission relies on robust \nsystems for assigning UIDs to link records of the mother or the mother–baby pair, integrating \nHIV information into existing MNCH cards or using electronic health information systems to \nfacilitate this process. Therefore, it is important to integrate PMTCT and paediatric HIV car",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that data tools must follow mother–baby pairs between service points and facilities, relying on unique identifiers, integration of HIV information into maternal and child health cards or electronic systems. It recommends integrating PMTCT and paediatric HIV services and their monitoring with maternal, newborn and child health care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-069",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring key outcomes towards elimination of vertical transmission",
      "pageStart": 123,
      "pageEnd": 125,
      "target": "../sections/sec-069-353-monitoring-key-outcomes-towards-elimination.md",
      "narrative": null,
      "content": "transmission \nThe vertical transmission indicators recommended in this guidance reflect important updates \nto definitions and disaggregation for tracking progress and managing PMTCT programmes \nacross the array of services offered (Table 3.6). The indicators for monitoring vertical \ntransmission were updated in 2020 to focus on outcomes such as viral suppression and early \ninfant diagnosis in addition to intermediate outcomes such as ART coverage in pregnancy \nand breastfeeding and infant ARV prophylaxis. Seven indicators are designated as national \npriority indicators, linked to critical time",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the updated vertical transmission indicators, which since 2020 emphasize results like maternal viral suppression and early diagnosis of infants, with seven designated national priority indicators tied to key points in the risk period. A figure maps maternal and child health service points to the patient monitoring tools used at each, such as registers and cards for antenatal care, delivery and postnatal care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p124",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 124,
      "pageEnd": 124,
      "target": "../figures/vfig-p124.webp",
      "narrative": "draft",
      "content": "Fig. 3.6, a diagram summarizing key patient monitoring tools for the PMTCT cascade across service delivery settings. Along a 'Timing of diagnosis' arrow are four columns, Preconception, Pregnancy, Labour & delivery and Postnatal, each listing tools such as the HIV care & treatment card, maternal health card, ANC register, labour record, L&D register, child health card, HEI card and register, PNC register and MIP register. Service delivery points shown include family planning, HIV prevention services, other outpatient services, antenatal care, labour & delivery and MNCH, with referral and linkage to MNCH/PMTCT services.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-070",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Follow-up of the mother–infant pair",
      "pageStart": 125,
      "pageEnd": 129,
      "target": "../sections/sec-070-354-follow-up-of-the-motherinfant-pair.md",
      "narrative": null,
      "content": "Strengthening follow-up of mother–infant pairs, from ANC, labour and delivery (maternity) \nand postpartum maternal visits to child health clinics and ART services, remains critical \nfor elimination of vertical transmission and improved maternal and child health outcomes. \nA mother–infant pair register can be used for this (see Box 3.9). Monitoring tools should \ncapture the full spectrum of care that HIV-exposed infants should receive, that is, ARV and \nco-trimoxazole preventive therapy, timely HIV nucleic acid testing, appropriate infant-feeding \npractices, testing for final outcome status, an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses following mother–infant pairs from antenatal and delivery care to child health and ART services, using a mother–infant pair register and recording the mother's identifier on the infant's record. It lists the care HIV-exposed infants should receive and be monitored for, such as prophylaxis, timely nucleic acid testing, feeding practices and final outcome testing. It sets out the minimum dataset for exposed infants, highlighting updates since 2017.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-071",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring TB/HIV",
      "pageStart": 129,
      "pageEnd": 130,
      "target": "../sections/sec-071-36-monitoring-tbhiv.md",
      "narrative": null,
      "content": "Box 3.11 What is new in TB–HIV patient monitoring in 2020 \n•\t Updates to the TB–HIV indicators on TB preventive treatment (TPT) initiation and \ncompletion; TB diagnostic testing with molecular WHO-approved rapid diagnostics \namong people living with HIV; and TB burden among new ART patients \n•\t Updated TPT regimens, including 6H and shorter rifamycin-based regimens\n•\t Five additional indicators reflecting the TB screening and diagnostic cascade, which \nare recommended for countries that are a priority for high-burden TB–HIV.\nHigh comorbidity and mortality due to HIV-associated TB require an in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes 2020 updates to TB–HIV patient monitoring, including revised indicators on TB preventive treatment and rapid molecular TB testing and new shorter preventive regimens. It recalls WHO's collaborative TB/HIV activities and lists recent recommendations relevant to recording and reporting, such as new screening tools and starting ART within two weeks of TB treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-072",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB in people living with HIV captured in the HIV patient monitoring system",
      "pageStart": 130,
      "pageEnd": 131,
      "target": "../sections/sec-072-361-tb-in-people-living-with-hiv-captured-in-the.md",
      "narrative": null,
      "content": "monitoring system\nServices to reduce the burden of TB among people living with HIV, which are measured and \nreported from the HIV patient monitoring system, include initiation of ART, intensified case-\nfinding, TPT and infection control (28). The 2020 Consolidated HIV strategic information \nguidelines include TPT completion as a national core indicator as well as key indicators to \ncapture the TB diagnostic and care cascade for high TB–HIV burden countries. Box 3.12 \npresents important interventions that can be measured using the HIV patient monitoring \nsystem.\nBox 3.12 TB–HIV indicators \nNati",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes TB-related services for people living with HIV that are measured through the HIV patient monitoring system, such as ART, case-finding, preventive treatment and infection control. A box lists the TB–HIV indicators, including national core indicators on preventive treatment initiation and completion and priority indicators on diagnostic testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-073",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV in presumptive and diagnosed TB patients captured in the TB patient monitoring system",
      "pageStart": 131,
      "pageEnd": 131,
      "target": "../sections/sec-073-362-hiv-in-presumptive-and-diagnosed-tb-patients.md",
      "narrative": null,
      "content": "TB patient monitoring system\nThe TB definitions and reporting framework with integrated HIV recording and reporting \nrequirements have been developed and updated previously by WHO (4). These guidelines \nprovide, in addition, a list of supplementary recommended HIV data elements to be included in \nprogramme-specific TB monitoring tools.\nMonitoring of HIV among TB patients is based on a standardized TB patient treatment card \nand registers and reports using globally standardized definitions (4). Although forms and \nregisters may vary slightly between countries, the core data collected and defini",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how HIV among TB patients is monitored through standardized TB treatment cards, registers and quarterly reports, increasingly in electronic systems such as DHIS2. It notes the need to reconcile ART and TB registers for indicators on ART among TB patients and that other TB–HIV indicators come from TB programme records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-074",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Coordination of care, treatment and patient monitoring",
      "pageStart": 131,
      "pageEnd": 134,
      "target": "../sections/sec-074-363-coordination-of-care-treatment-and-patient-m.md",
      "narrative": null,
      "content": "Robust mechanisms for effective coordination, referral and communication between TB \nand HIV services should be established to ensure effective care and treatment of both \ndiseases. Electronic data systems can facilitate integrated patient monitoring, which captures \ninformation on how well HIV prevention, diagnosis and care or referral for HIV care take place \nwithin TB programmes, and how well TB screening, prevention and treatment are carried \nout in HIV care/ART programmes. Some of the core indicators require data collection and \nreconciliation by the national HIV and TB programmes in tand",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for strong coordination, referral and communication between TB and HIV services, supported by electronic systems and co-located clinics, to ensure joint care and reconciled records. It tabulates TB–HIV data elements for HIV patient cards and registers. It also lists additional HIV data elements recommended for TB treatment cards, such as unique identifier, CD4 count, viral load and ARV regimen.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-075",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring service delivery for HIV treatment and care",
      "pageStart": 134,
      "pageEnd": 134,
      "target": "../sections/sec-075-37-monitoring-service-delivery-for-hiv-treatment.md",
      "narrative": null,
      "content": "and care",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading fragment reading 'and care', from the section title on monitoring service delivery for HIV treatment and care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-076",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 134,
      "pageEnd": 135,
      "target": "../sections/sec-076-371-introduction.md",
      "narrative": null,
      "content": "In 2021 WHO released updated recommendations on treatment and care service delivery for \npeople living with HIV (3) with a series of recommendations and good practice statements \nintended to promote continued improvements in access to ART, to simplify care delivery for \nproviders and end users and to support return to care for those who have disengaged (Box \n3.15). These recommendations include approaches for DSD of HIV treatment, recognizing \nthe diverse needs of people living with HIV and adapting accordingly how HIV services are \nprovided. \nThis section presents eight key WHO 2021 recommend",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces WHO's 2021 service delivery recommendations for HIV treatment and care, aimed at improving access, simplifying care and supporting return to care. It notes that the section presents eight key recommendations supporting differentiated service delivery and its monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-077",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview of DSD",
      "pageStart": 135,
      "pageEnd": 137,
      "target": "../sections/sec-077-372-overview-of-dsd.md",
      "narrative": null,
      "content": "DSD is a person-centred approach that simplifies and adapts HIV services across the care and \ntreatment cascade to reflect the needs and preferences of people living with HIV or vulnerable \nto infection. At the same time, it optimizes the use of available health system resources. “DSD \nseeks to create efficiencies in HIV service delivery to achieve programme expansion, while \nensuring that care meets the diversity of patient needs” (33). It entails programmatic shifts in \nthe way services are targeted and delivered, focusing on four building blocks:\n1.\t what – the type of services delivered\n2.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines differentiated service delivery as a person-centred approach that adapts HIV services to people's needs while using resources efficiently, built on four elements: what, where, who and when. It describes four categories of differentiated ART models, from health worker-managed groups to individual facility and community models. It summarizes WHO recommendations on less frequent visits and refills, community delivery and task sharing with nurses, community health workers and lay providers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-078",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring DSD",
      "pageStart": 137,
      "pageEnd": 138,
      "target": "../sections/sec-078-373-monitoring-dsd.md",
      "narrative": null,
      "content": "Patient monitoring systems must provide accurate and timely data on the diverse services \nand delivery models for DSD. Doing this requires adaptation of patient monitoring systems \nand tools and the introduction of indicators to monitor the unique aspects of DSD (36, 37). \nUpdates have been made to the HIV treatment and care patient card (see Web Annex H), ART \nregister (Web Annex K), HIV cross sectional report (Web Annex L) and ART cohort report \n(Web Annex M) to enable monitoring of patients engaged in differentiated ART models. \nThe patient monitoring system should capture key information i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that patient monitoring systems and tools must be adapted to capture data from differentiated service delivery models, with updated patient cards, registers and reports. It stresses that the linked facility keeps clinical responsibility and that community site data should be entered promptly into facility systems to avoid parallel reporting and support tracking of missed pick-ups.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-079",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key DSD indicators",
      "pageStart": 138,
      "pageEnd": 138,
      "target": "../sections/sec-079-374-key-dsd-indicators.md",
      "narrative": null,
      "content": "Table 3.8 summarizes key indicators, drawn from the HIV patient monitoring system, \nrecommended to monitor the coverage, uptake and clinical outcomes of DSD. These indicators \ndo not, however, represent the entire range of DSD indicators required for programme \nmonitoring and management. For this, countries should consider a wider range of indicators \nincluding the experience or satisfaction of clients and health care workers, facility uptake of \nDSD, efficiency of DSD services in terms of service delivery cost to facilities, out-of-pocket costs \nto clients, drug wastage, clinical consultation",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that the key indicators for differentiated service delivery cover coverage, uptake and clinical outcomes, but that programme management also needs measures of client and worker experience, costs, efficiency and workload. It points to forthcoming WHO guidance and an existing ICAP framework for monitoring and evaluation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-080",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Multi-month ARV dispensing",
      "pageStart": 138,
      "pageEnd": 140,
      "target": "../sections/sec-080-375-multi-month-arv-dispensing.md",
      "narrative": null,
      "content": "This key indicator, DSD.1, multi-month ARV dispensing is recommended by WHO, the United \nStates President’s Emergency Plan for AIDS Relief (PEPFAR) and UNAIDS and is now included \nas a Global AIDS Monitoring (GAM) indicator. This is recommended as the minimum indicator \nfor monitoring when DSD ART is rolled out in countries. As DSD implementation is expanded, \nfive core indicators are recommended to track progress and patient outcomes for established \nprogrammes (Table 3.8 and Chapter 8). \nSome key considerations for implementation of multi month ARV dispensing and resulting \nmonitoring includ",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents multi-month ARV dispensing (indicator DSD.1) as the minimum indicator when rolling out differentiated service delivery (DSD) for HIV treatment, noting it is also a Global AIDS Monitoring indicator. It suggests aligning drug pick-ups, clinical visits and dispensing for co-infections, and Table 3.8 defines five priority DSD indicators, including enrolment, retention and viral suppression in DSD models. Programmes are also advised to monitor whether eligibility criteria for DSD are applied correctly.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-081",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Clinical outcomes among people living with HIV enrolled in DSD ART models",
      "pageStart": 140,
      "pageEnd": 141,
      "target": "../sections/sec-081-376-clinical-outcomes-among-people-living-with-h.md",
      "narrative": null,
      "content": "ART models\nAssessment of key clinical outcomes among people receiving differentiated ART can be used \nto evaluate the impact of DSD models. Outcomes such as ART retention (indicator DSD.4) and \nviral suppression (indicator DSD.5) can be compared before and after implementation of DSD. \nThe retention period would be defined for a relevant period (for example, 12 or 24 months after \nART initiation). \nAs various DSD models are implemented, conducting periodic assessments of patients’ \nclinical outcomes enrolled in DSD ART models is recommended. Adapted quarterly ART \ncohort reports (Web Annex M)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how retention and viral suppression among people in DSD treatment models can be compared before and after implementation and assessed through adapted cohort reports. It stresses including DSD clients in cohort monitoring without double counting, and notes how treatment interruption is defined for people on longer dispensing intervals.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-082",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tracing interventions to identify people who interrupt treatment and support re-engagement in care",
      "pageStart": 141,
      "pageEnd": 143,
      "target": "../sections/sec-082-377-tracing-interventions-to-identify-people-who.md",
      "narrative": null,
      "content": "treatment and support their re-engagement in care.\nAs DSD models of care aim to enhance coverage, efficiency and quality of care, additional \nM&E approaches may be useful – for example, surveys of patient satisfaction and provider \nsatisfaction, assessment of providers’ patient load and productivity and cost-effectiveness \nevaluations of DSD models. Findings from these assessments may be used to track progress in \nimplementation of key DSD elements (for example, establishment of specific DSD models, roles \nand responsibilities in ART distribution, use of patient monitoring tools) within facili",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Suggests additional evaluation of DSD models, such as patient and provider satisfaction and cost-effectiveness, with indicators disaggregated by age, gender and key population. It describes tracing people who interrupt treatment, incorporating ART pick-up dates into tools to detect missed visits, and lists data to record on tracing outcomes and reasons.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-083",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key data elements to monitor for DSD ART",
      "pageStart": 143,
      "pageEnd": 145,
      "target": "../sections/sec-083-378-key-data-elements-to-monitor-for-dsd-art.md",
      "narrative": null,
      "content": "DSD care elements should be integrated into existing patient monitoring tools and EMR \nsystems in line with updates to HIV treatment and care service delivery recommendations. \nUpdates have been made to the HIV care and treatment patient card (see Web Annex H) to \ncapture ART initiation outside health facilities and enrolment in DSD ART models as well as \ndelivery of community-based interventions to improve retention and psychosocial interventions \nfor adolescents and young adults living with HIV. The minimum dataset for HIV treatment \n(Web Annex A) has also been updated to include key data el",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how DSD elements should be built into patient cards, registers and electronic records, including ART initiation outside facilities, DSD model enrolment and community and psychosocial interventions. It highlights monitoring CD4 at presentation and on return to care to identify advanced disease, and lists key data elements for DSD clients, such as pick-up dates and reasons for exclusion from DSD.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-084",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring considerations for community ART services",
      "pageStart": 145,
      "pageEnd": 150,
      "target": "../sections/sec-084-379-monitoring-considerations-for-community-art.md",
      "narrative": null,
      "content": "Key monitoring considerations related to the initiation and delivery of ART outside of health \nfacilities and other aspects of community DSD include the following: \n•\t Development, use and storage of facility and community tools. The HIV patient \ncard/folder, the paper or e-register should remain at the facility. Since patient monitoring \ntools are not available at the point of service delivery for community-based DSD models, \nmonitoring tools for community-delivered ART services will need to be developed and \nimplemented. See Web Annex I for an example of a community ART tool and Box 3.20 for",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out monitoring considerations for community-delivered ART, including developing community tools while keeping patient records at facilities, and protecting data confidentiality and security in community settings. It lists existing community ART and adherence club tools that countries can adapt. A Mozambique case study describes how its patient monitoring system, tools and DSD indicators were strengthened.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p149",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 149,
      "pageEnd": 149,
      "target": "../figures/vfig-p149.webp",
      "narrative": "draft",
      "content": "Fig. 3.7, an icon-based flow diagram of data flow from the health facility to the Ministry of Health in Mozambique. Data move from the health facility to the master card and then to the EMR, which feeds three implementing partners; their data flow (shown with a chart icon) to CDC/USAID, which passes them to the MOH. Source: Ministry of Health of Mozambique.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-085",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key populations",
      "pageStart": 150,
      "pageEnd": 150,
      "target": "../sections/sec-085-38-key-populations.md",
      "narrative": null,
      "content": "For monitoring for key populations, WHO recommends the following: All patient monitoring \nsystems should be governed by frameworks and regulations for data protection and \nconfidentiality. Individual-level information related to key populations and behaviours that \nmight be criminalized or stigmatized should not be included in ART registers or reported up to \nsubnational or national data management units. Information about behaviours, comorbidities \nor other medications dispensed, and referrals for prevention services may be noted in clinical \nrecords such as the HIV patient card only if that",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States WHO recommendations for monitoring key populations: data protection frameworks, no key population or criminalized-behaviour information in ART registers or reports, and clinically useful information only in secure patient records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-086",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 150,
      "pageEnd": 151,
      "target": "../sections/sec-086-381-background.md",
      "narrative": null,
      "content": "Data relating to an individual’s behaviours can be important for patient management and \nprogramme monitoring. However, in many settings consensual same-sex sexual activity, sex \nwork, cross-dressing or drug use are stigmatized and even criminalized. \nCollecting identifiable information linked to these behaviours from people receiving ART raises \nthe potential for negative consequences both for individual clients and for providers delivering \nHIV services. These consequences may include the following:\n1.\t Data related to criminalized behaviours can be used by law enforcement officers and other",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why collecting identifiable data on stigmatized or criminalized behaviours from people on ART can harm clients and providers, through law enforcement use, underreporting and discrimination. It notes that behaviours change over time, so labelling someone as a key population member may not stay meaningful.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-087",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Considerations for patient management",
      "pageStart": 151,
      "pageEnd": 151,
      "target": "../sections/sec-087-382-considerations-for-patient-management.md",
      "narrative": null,
      "content": "While HIV prevention services can be provided without the need to collect personally \nidentifying information and using anonymous UID codes to allow longitudinal monitoring, in \nmost settings it is required that individuals receiving HIV treatment are identified. \nBecause of the sensitivities around information that might indicate an individual’s engagement \nin stigmatized or criminalized behaviours or their key population status, only information that \nis clinically relevant should be included in clinical records where individuals are personally \nidentified. Clinical information such as alcoh",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises that only clinically relevant information, such as drug dependence, opioid agonist therapy, hormone therapy or sexual risk, be recorded in identifiable clinical records for people on HIV treatment. Partner-related prevention interventions can be noted on the back of the patient card.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-088",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Considerations for programme monitoring",
      "pageStart": 151,
      "pageEnd": 153,
      "target": "../sections/sec-088-383-considerations-for-programme-monitoring.md",
      "narrative": null,
      "content": "ART registers can be accessed by a variety of facility staff and other staff and so may be \ndifficult to keep confidential. For this reason, ART registers are not appropriate for the \ncollection of data related to key population status. Ensuring sufficient ART coverage among key \npopulations living with HIV, however, is critical for a successful HIV response. \nRoutine programme data reported up to subnational and national data management units \nshould not include the key population category or risk behaviour if this information can be \nlinked to an individual. HIV programme monitoring specific",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that ART registers are not suitable for recording key population status, and that ART coverage among key populations should instead be measured through bio-behavioural and other surveys or de-identified case surveillance. It describes how key population programmes can confirm linkage to treatment while protecting identities, with an example from the EpiC programme in Malawi using triplicate referral tickets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-089",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Considerations when collecting data about gender",
      "pageStart": 153,
      "pageEnd": 153,
      "target": "../sections/sec-089-384-considerations-when-collecting-data-about-ge.md",
      "narrative": null,
      "content": "Trans and gender diverse people is an umbrella term for people whose gender identity and \nexpression do not conform to the norms and expectations traditionally associated with the \nsex assigned to them at birth. Since gender is described differently in different countries and \ncultures, gender identity categories include male, female and other, where other includes trans \nand gender diverse people including those who choose an identity other than male or female.\nIn settings where being trans or gender diverse is highly stigmatized or penalized, and to \nincrease client safety, it is acceptable",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines trans and gender diverse people and advises recording both gender identity and sex assigned at birth on clinical records, or only male and female where being trans is highly stigmatized or penalized.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-090",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Minimum dataset and key definitions for HIV patient monitoring",
      "pageStart": 153,
      "pageEnd": 158,
      "target": "../sections/sec-090-39-minimum-dataset-and-key-definitions-for-hiv-p.md",
      "narrative": null,
      "content": "monitoring \n3.9.1 Minimum dataset \nThe minimum dataset contains core demographic, clinical and laboratory data. Each data \nelement has a standardized definition and prescribed coding categories. The minimum dataset \ncomprehensively assesses all people living with HIV tested and receiving HIV care. The \nprimary purpose is to standardize patient information with a simplified and harmonized set \nof essential data elements relevant to core patient management and programme monitoring. \nStandardization also enables programme staff to compare data across populations, time, \ngeographical areas and set",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the minimum dataset for HIV patient monitoring, a standardized set of demographic, clinical and laboratory data elements with defined coding, and highlights new elements in the 2022 version. It then sets out key definitions along the care cascade, such as enrolment in HIV care, ART start, transfers, loss to follow-up and treatment outcomes. It notes WHO's recommendation of rapid ART initiation within seven days of diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p158",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 158,
      "pageEnd": 158,
      "target": "../figures/vfig-p158.webp",
      "narrative": "draft",
      "content": "A page render showing the continuation of Table 3.9, 'Key terms and definitions used in this guidance for HIV patient monitoring', with two rows: 'Net current cohort (cohort analysis report)' and 'Final outcome status of PMTCT' with their definitions. Below it, Box 3.24 lists WHO recommendations on standardized data collection and reporting tools (patient card or EMR for every person confirmed HIV-positive, ART registers at all ART sites, and routine minimum reporting by community ART providers).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-091",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Standardized data collection and reporting tools for HIV patient testing, treatment and care",
      "pageStart": 158,
      "pageEnd": 159,
      "target": "../sections/sec-091-310-standardized-data-collection-and-reporting-t.md",
      "narrative": null,
      "content": "HIV patient testing, treatment and care\nBox 3.24 Standardized data collection and reporting tools: WHO \nrecommendations \n•\t Health workers should create an HIV treatment and care patient card or EMR \nfor every person who is confirmed HIV-positive and subsequently record care, \nregardless of the entry point (that is, HIV, MNCH, TB service). \n•\t ART registers or electronic equivalents should be kept and used at all sites where \nART is provided. \n•\t Community ART providers engaged in ART delivery should routinely monitor and \nreport on a minimum key set of data in a simple, standardized way.\nFig.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives WHO recommendations on standardized tools: a patient card or electronic record for every person diagnosed with HIV, ART registers wherever ART is provided, and simple standardized reporting by community ART providers. It describes the transfer and referral form and an overview figure of monitoring tools across HIV, maternal and child health and TB settings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p159",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 159,
      "pageEnd": 159,
      "target": "../figures/vfig-p159.webp",
      "narrative": "draft",
      "content": "Fig. 3.8, a diagram of the standardized HIV patient monitoring system and linkages by service delivery area and level. Three facility columns, MNCH, HIV and TB, show patient records (e.g. HIV card, maternal/child health cards, TB treatment card), registers (ART, HTS, ANC/L&D/HEI/MIP, TB laboratory registers) and reports, linked by UID, ANC number and TB register number. Community tools (community health worker tools, community ART tool, DSD tools, community testing tools) feed upward, and facility data flow to the HIV cross-sectional report and ART cohort report, which inform indicators for patient management, programme monitoring and management at subnational and national level.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-092",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tools for facility-based monitoring of HIV treatment and care",
      "pageStart": 159,
      "pageEnd": 161,
      "target": "../sections/sec-092-3101-tools-for-facility-based-monitoring-of-hiv.md",
      "narrative": null,
      "content": "The HIV patient monitoring system is designed to capture and retain data on all people with \na confirmed HIV diagnosis and follow them through the cascade of HIV care services, from \ndiagnosis and ART initiation to sustained viral suppression. Patient monitoring tools should \nculminate in reports that are acted on. Each report should list the suggested name of who at \neach level should act on the outcomes of the report, how and by when. For guidance on data \nuse, see section 3.11 on improving the quality and use of individual-level data.\nA health care worker takes the following steps to start",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the facility-based HIV patient monitoring system follows people from diagnosis through ART to viral suppression and should produce actionable reports. It explains the steps for starting a patient card at any entry point and in integrated settings, and lists updates to the patient card, such as TB diagnostic tests, preventive therapy codes and immunizations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-093",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV transfer or referral form",
      "pageStart": 161,
      "pageEnd": 161,
      "target": "../sections/sec-093-3102-hiv-transfer-or-referral-form.md",
      "narrative": null,
      "content": "To the extent possible, if a person is referred from or transfers from another facility or \ncommunity ART site for care and treatment, key information should be recorded and sent with \nthe patient for continuity of care, retention on ART and maintenance of viral suppression, as \nwell as to avoid duplication in record-keeping and reporting. The generic HIV care referral form \nincludes information taken primarily from the front of the HIV patient card and comes with \na “counter-referral” section that can be cut off and sent back to the referring facility so that \nit is notified of a successful r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the HIV transfer and referral form, which carries key patient information between facilities and community ART sites and includes a counter-referral slip confirming successful transfer.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-094",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ART register",
      "pageStart": 161,
      "pageEnd": 163,
      "target": "../sections/sec-094-3103-art-register.md",
      "narrative": null,
      "content": "Box 3.26 ART register: WHO recommendation \nAll people living with HIV who initiate treatment should be entered into a longitudinal \nART register or electronic equivalent when they start ART, preferably within seven days \nof diagnosis.\nThe ART register: \n•\t contains a subset of key information from the HIV patient card/folder in certain settings; \n•\t is organized by the month and year (cohort) in which the patient starts ART, regardless of \nwhere started;\n•\t records the follow-up of patients on ART over time, including CD4 count and VL and \nenrolment in DSD; \n•\t is used to aggregate data into t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States WHO's recommendation that everyone starting ART be entered in a longitudinal ART register organized by start cohort and used to compile cohort and cross-sectional reports. It explains benefits for integrated settings and lists updates to the register, such as DSD enrolment, weight gain as a toxicity and fluconazole prophylaxis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-095",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cross-sectional and cohort reports",
      "pageStart": 163,
      "pageEnd": 165,
      "target": "../sections/sec-095-3104-cross-sectional-and-cohort-reports.md",
      "narrative": null,
      "content": "Two reports aggregate data from the ART register: \n•\t The cross-sectional report tallies the cumulative and current numbers of people living with \nHIV in care and on ART, disaggregated by age and sex quarterly to annually. \n•\t The cohort report records outcomes of groups of people living with HIV who started ART \nin the same month and year at 6, 12, 24 months, etc., after ART initiation. \nCross-sectional report\nThe cross-sectional report provides a snapshot of patients’ status at one point in time. The \nnumber of people living with HIV who have started treatment (key indicator ART.4 New ART \np",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the two reports built from the ART register: a cross-sectional report of current and cumulative patients, and a cohort report of outcomes at set intervals after starting ART. It describes how indicators such as new ART patients, late initiation and people on ART are drawn from these reports. It lists updates, including viral load timing and outcomes for people in DSD models.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-096",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Other recommended tools to facilitate HIV patient monitoring",
      "pageStart": 165,
      "pageEnd": 166,
      "target": "../sections/sec-096-3105-other-recommended-tools-to-facilitate-hiv-p.md",
      "narrative": null,
      "content": "WHO recommends additional tools to facilitate patient monitoring, including monitoring ART \nadherence from pharmacy records (Box 3.29). \nBox 3.29 Other WHO-recommended tools for HIV patient \nmonitoring \n•\t Appointment book in health facilities with paper reporting, for tracking patients \nwho miss scheduled visits or drug pick-ups \n•\t List of recommended data elements for monitoring adherence in people on ART \nfrom a pharmacy record: \n\t–\ndate of pick-up \n\t–\nnumber of days for which ARV drugs were dispensed \n\t–\nARV regimen dispensed.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists other recommended monitoring tools: appointment books to track missed visits and pharmacy data elements for monitoring adherence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-097",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tools for community - delivered treatment and care services",
      "pageStart": 166,
      "pageEnd": 168,
      "target": "../sections/sec-097-3106-tools-for-community---delivered-treatment-a.md",
      "narrative": null,
      "content": "Community-based ART patient monitoring tool \nUnder the DSD guidelines recommended by WHO in 2021, clients may initiate ART outside \nhealth facilities and clients established on ART may have less frequent clinical visits and \nmedication pick-up, and they may access more decentralized service delivery points, including \ncommunity-based services (3). To accommodate larger numbers of people enrolled in HIV \ncare programmes, WHO also recommends task shifting to allow clinical settings to focus on \nindividuals who are initiating treatment or who are unwell and to delegate the monitoring of \npatients",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the role of community ART providers under WHO's 2021 DSD recommendations, including task shifting, linking clients to facilities and distributing medicines in communities. It introduces a community-based ART monitoring tool and notes links to maternal, child health and TB services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-098",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Improving the quality and use of individual-level data to strengthen HIV patient monitoring and care",
      "pageStart": 168,
      "pageEnd": 168,
      "target": "../sections/sec-098-311-improving-the-quality-and-use-of-individual.md",
      "narrative": null,
      "content": "to strengthen HIV patient monitoring and care",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading fragment on improving the quality and use of individual-level data for HIV patient monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-099",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Importance of strengthening the quality of individual-level HIV patient monitoring data",
      "pageStart": 168,
      "pageEnd": 173,
      "target": "../sections/sec-099-3111-importance-of-strengthening-the-quality-of.md",
      "narrative": null,
      "content": "patient monitoring data\nGood-quality individual-level data are important to ensure that health care providers make \nwell-informed decisions for improved HIV patient management. As countries move towards \nthe UN Political Declaration 95–95–95 targets for HIV treatment and care, it is now more \nimportant than ever to collect and report accurate data in real time to understand where gaps \nin service delivery remain and ensure the use of data to improve quality of care and patient \noutcomes.\nEfforts should be made to ensure that \ndata quality assessments are not singular \nevents implemented on an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses the importance of good-quality individual-level data for patient management and progress towards the 95–95–95 targets, with data quality work institutionalized rather than ad hoc. It sets out data quality dimensions, confidentiality principles and a systems approach to data quality improvement. It describes practical checks, such as reconciling high viral load results between laboratory systems and facility registers. It ends with district-level triangulation of data sources to improve model inputs and subnational estimates.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p171",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 171,
      "pageEnd": 171,
      "target": "../figures/vfig-p171.webp",
      "narrative": "draft",
      "content": "Fig. 3.9, an example data quality improvement and use framework in three columns: focus areas, major activities and resources. The focus areas are DQI, DQA and Data use, each with a list of activities such as training of health care workers and data clerks, routine DQA and remedial action plans, and data review meetings at facilities and districts. Resources include DQI teams at all levels, infrastructure and hardware, standardized HIV patient monitoring tools, SOPs/job aids, DQA tools and EMR systems. Source: adapted from PEPFAR Ethiopia data improvement and use initiative campaign, 2019.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p173",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 173,
      "pageEnd": 173,
      "target": "../figures/vfig-p173.webp",
      "narrative": "draft",
      "content": "Fig. 3.10, a six-step process diagram with icons showing steps for implementing routine HIV data quality assurance activities at health facilities: Determine the purpose; Select levels and sites to be included; Identify indicators, data sources and reporting period; Conduct site visits; Review outputs and findings; Develop a system strengthening plan, including follow-up actions. Source: WHO, 2020.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-100",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data use for improved service delivery",
      "pageStart": 173,
      "pageEnd": 178,
      "target": "../sections/sec-100-3112-data-use-for-improved-service-delivery.md",
      "narrative": null,
      "content": "DQI is ultimately useful only if accompanied by enhanced data use to improve service \ndelivery and health outcomes. Using data at the level of collection improves clinical care and \nmanagement, strengthens the health service and improves the quality of the data. (See Box \n3.33 for a country example of strengthening data use to improve HIV patient management \nand monitoring.) Enhanced data analysis and use can provide additional information to correct \nquality of care issues and to better understand service delivery gaps as well as to improve \nprogramme management and surveillance and to inform",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Argues that data quality improvement matters only if data are used to improve services, and illustrates data use at patient, facility, district and national levels. It describes standardized information products, training, mentorship and supportive supervision, and making reports actionable with clear responsibilities. It also covers analysing loss-to-follow-up data to support tracing and lists data-use tasks for different facility staff.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p174",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 174,
      "pageEnd": 174,
      "target": "../figures/vfig-p174.webp",
      "narrative": "draft",
      "content": "Fig. 3.11, a tiered diagram of examples of data use at different levels. At facility level (facility computers and paper register): patient management, facility management, nationally required and staff accountability reports. At district level: service delivery quality and comparisons, district outcomes and burden, and informing intervention discussions. At subnational level: epidemiological and temporal trends, business plans, projections for unmet need and data triangulation. At national level: impact of HIV and TB services, informing policy change and reporting on international obligations. Source: University of Cape Town, 2021.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p176",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 176,
      "pageEnd": 176,
      "target": "../figures/vfig-p176.webp",
      "narrative": "draft",
      "content": "Fig. 3.12, within Box 3.33, a grouped bar chart of completion of the first viral load test (3–6 months) after ART initiation by clinic in Subdistrict X, comparing quarter 4 2020 and quarter 1 2021 for Clinics A–F on a 0–100% axis. Clinics D, E and F are at about 80–90%, Clinics A and B at about 60–70%, and Clinic C, circled, is lowest at about 40% falling to under 40%. Source: University of Cape Town, 2021.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-101",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Adaption and implementation of the HIV patient monitoring system",
      "pageStart": 178,
      "pageEnd": 178,
      "target": "../sections/sec-101-312-adaption-and-implementation-of-the-hiv-patie.md",
      "narrative": null,
      "content": "monitoring system",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading fragment on adapting and implementing the HIV patient monitoring system.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-102",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 178,
      "pageEnd": 178,
      "target": "../sections/sec-102-3121-introduction.md",
      "narrative": null,
      "content": "This section provides guidance on steps for adapting and implementing all or part of the \nHIV patient monitoring system outlined in this document. It includes recommendations for \ncoordinating across programmes and services and for the transition from a previous version \nof the patient monitoring system to an updated one. It lays out requirements for a patient \nmonitoring system that can be applied to any system along the paper-to-electronic continuum. \nThe generic tools and accompanying recommendations in this guidance should be adapted \nand customized to fit the specific setting of each coun",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces guidance on adapting and implementing the HIV patient monitoring system, from coordination across programmes to transitioning between versions, on paper or electronic platforms.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-103",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Steps for country adaptation of the guidance",
      "pageStart": 178,
      "pageEnd": 182,
      "target": "../sections/sec-103-3122-steps-for-country-adaptation-of-the-guidanc.md",
      "narrative": null,
      "content": "The generic HIV patient monitoring system is designed to support both integrated service \ndelivery at the facility level and facilities and community ART and testing sites where services \nremain separate but need to be closely linked. “Integration” refers to HIV services included in \nthe same visit (by the same health worker or within a clinical team) along with ANC, labour \nand delivery, postpartum and new born care and with TB and other acute and chronic care \nservices. While not providing a detailed methodology, Table 3.11 shows the recommended \nactions to take (not necessarily in the order",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the generic HIV patient monitoring system supports both integrated services and linked separate sites, and lists special considerations such as the service delivery model. Table 3.11 sets out 16 adaptation steps, from forming a technical working group and inventorying tools to defining indicators, training, coordinating partners and ensuring sustainable funding. A box describes the collaboration needed across HIV and other programmes, including standard minimum datasets and unique identifiers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-104",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Human resources and capacity-building",
      "pageStart": 182,
      "pageEnd": 186,
      "target": "../sections/sec-104-3123-human-resources-and-capacity-building.md",
      "narrative": null,
      "content": "Patient monitoring requires the participation of a wide range of staff with overlapping \nresponsibilities. Shifting tasks to lower-level cadres and even lay providers can increase what \nthe programme can accomplish. Table 3.12 suggests a breakdown of different roles and \nresponsibilities among staff members. In the case of electronic systems, “EMR” may replace \n“patient record” and “electronic register” may replace “register”, but staff responsibilities \nwill remain the same. Once the roles and responsibilities of each staff member have been \nidentified, it is important to provide the necessar",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes staffing for HIV patient monitoring in WHO's HIV strategic information guidelines, with a table assigning roles from district teams to clinicians, data clerks and lay providers, and notes that task-shifting can extend capacity. It sets out recommendations for training, clinical mentoring and supportive supervision, including what mentoring visits should cover.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-105",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Transitioning to digital health systems",
      "pageStart": 186,
      "pageEnd": 187,
      "target": "../sections/sec-105-3124-transitioning-to-digital-health-systems.md",
      "narrative": null,
      "content": "Over time many HIV high burden countries have transitioned from paper-based systems \ntowards the use of electronic information systems, including EMRs. This transition is driven \nby (a) the increasing difficulty of accurately and reliably retrieving data from a paper-based \npatient record system, (b) the time and effort required to maintain a paper-based system as \nthe volume of data increases, (c) the need to support integration and linkage across different \nservice delivery areas and sites over time, and d) increasing investments and adoption of \ndigital health innovations by both countries",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why many high-burden countries are moving from paper to electronic HIV patient records, such as difficulty retrieving data and the need for linkage across services, while noting that coverage is incomplete. The block also includes the end of a box on supportive supervision using checklists.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-106",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 187,
      "pageEnd": 191,
      "target": "../sections/sec-106-references.md",
      "narrative": null,
      "content": "1.\t Consolidated HIV strategic information guidelines: driving impact through programme \nmonitoring and management. Geneva: World Health Organization; 2020 (https://www.who.\nint/publications/i/item/9789240000735, accessed 24 June 2022).\n2.\t Consolidated guidelines on HIV prevention, testing, treatment, service delivery and \nmonitoring: recommendations for a public health approach. Geneva: World Health \nOrganization; 2021 (https://www.who.int/publications/i/item/9789240031593, accessed 23 \nJune 2022).\n3.\t Updated recommendations on service delivery for the treatment and care of people living \nw",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for chapter 3 of the HIV strategic information guidelines, citing mainly WHO HIV, testing and TB guidance and modelling and data-use studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-107",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 4 – Integrating related infections into HIV surveillance systems",
      "pageStart": 191,
      "pageEnd": 192,
      "target": "../sections/sec-107-chapter-4-integrating-related-infections-into-hi.md",
      "narrative": null,
      "content": "INTEGRATING RELATED \nINFECTIONS INTO HIV \nSURVEILLANCE SYSTEMS\n4\nKey recommendations\b\n162\n4.1\t Introduction\b\n163\n4.2\t Sexually transmitted infections\b\n164\n4.2.1 Background and rationale\b\n164\n4.2.2 Minimum dataset for STIs \b\n168\n4.2.3 Priority indicators for STIs \b\n169\n4.3\t Viral hepatitis\b\n171\n4.3.1 Background and rationale\b\n171\n4.3.2 Minimum dataset for viral hepatitis\b\n173\n4.3.3 Priority indicators for viral hepatitis \b\n174\n4.4\t Cervical cancer\b\n176\n4.4.1 Background and rationale\b\n176\n4.4.2 Minimum dataset for cervical cancer\b\n178\n4.4.3 Priority indicators for cervical cancer\b\n180\nReferences",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The opening page and contents of chapter 4, on integrating sexually transmitted infections, viral hepatitis and cervical cancer into HIV surveillance systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-108",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key recommendations",
      "pageStart": 192,
      "pageEnd": 193,
      "target": "../sections/sec-108-key-recommendations.md",
      "narrative": null,
      "content": "NEW   \u00071. \u0007Person-centred data should support the improved health and quality of \nlife of people over their lifetimes, with routine HIV systems monitoring \nrelated infections such as TB, STIs, hepatitis B and C, pre-invasive cervical \ndisease and cancer and noncommunicable diseases. \nNEW   \u00072. \u0007STI testing and treatment should be measured as part of HIV prevention, \ntesting and treatment programmes.\nNEW   \u00073. \u0007A recent record of STI symptoms, diagnoses or treatment should be \nrecorded in HIV data systems and included as a key event to trigger HIV \ntesting and prevention services.\nNEW   \u00074. \u0007He",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists five new key recommendations for chapter 4: person-centred HIV systems should monitor related infections, STI testing and treatment and recent STI history should be recorded, hepatitis B and C services should be measured for people with HIV and key populations, and cervical cancer screening should be recorded for women living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-109",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 193,
      "pageEnd": 194,
      "target": "../sections/sec-109-41-introduction.md",
      "narrative": null,
      "content": "The modes of transmission and epidemiology of a number of STIs and bloodborne infections \nsuch as viral hepatitis are similar to those of HIV, with overlapping risk profiles. Interventions \nto prevent, diagnose and treat these infections are often delivered through integrated or \nclosely linked services. As countries move toward operationalizing the wider use of individual-\nlevel data, these data systems will become an important tool for ensuring effective, high-\nquality services across not only the HIV cascade but also for the prevention, diagnosis and \ntreatment of other related infections.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that STIs and viral hepatitis share transmission routes and risk profiles with HIV and are often served through linked services, so person-centred data systems can support their monitoring and universal health coverage. It introduces a minimum dataset and indicators for STIs, hepatitis and cervical cancer, linked by unique identifiers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p194",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 194,
      "pageEnd": 194,
      "target": "../figures/vfig-p194.webp",
      "narrative": "draft",
      "content": "Fig. 4.1, a grouped bar chart with error bars of estimated new cases of four curable STIs among adults aged 15–49 years, by sex, in 2020. Totals are trichomoniasis 156.3 million (female 73.7m, male 82.6m), chlamydia 128.5 million (69.9m, 58.6m), gonorrhoea 82.4 million (35.9m, 46.4m) and syphilis 7.1 million (3.5m, 3.6m), with uncertainty ranges shown above each total. Source: WHO, 2021.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-110",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Sexually transmitted infections",
      "pageStart": 194,
      "pageEnd": 194,
      "target": "../sections/sec-110-42-sexually-transmitted-infections.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-111",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background and rationale",
      "pageStart": 194,
      "pageEnd": 198,
      "target": "../sections/sec-111-421-background-and-rationale.md",
      "narrative": null,
      "content": "More than one million curable STIs are acquired every day worldwide, primarily caused by \nChlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum (syphilis) and Trichomonas \nvaginalis (Fig. 4.1). In addition, more than one in every seven women are estimated to be \ninfected with human papillomavirus (HPV) which causes cervical cancer, and more than \n500 million people have genital herpes simplex virus (HSV) infection (11, 12). Population groups \nthat are especially vulnerable to STIs include sex workers and their clients, men who have sex \nwith men, trans and gender diverse people, ado",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the burden of STIs, with over a million curable infections a day, and the groups most vulnerable to them, with a figure of estimated 2020 cases of chlamydia, gonorrhoea, syphilis and trichomoniasis by sex. It links STIs to HIV acquisition and to the global health sector strategy for 2022–2030 and lists relevant WHO STI guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-112",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Minimum dataset for STIs",
      "pageStart": 198,
      "pageEnd": 199,
      "target": "../sections/sec-112-422-minimum-dataset-for-stis.md",
      "narrative": null,
      "content": "Table 4.1 presents a minimum set of data elements for monitoring STIs in individuals using \nHIV prevention services and people living with HIV. The data elements cover information \non both clinical diagnosis and testing. The lack of low-cost reliable POC tests for STIs apart \nfrom syphilis means that in many parts of the world individuals are treated for STIs based on \nsymptoms. For individuals treated based on symptoms, clear and consistent case definitions \nare critical if the data are to be used for monitoring appropriate treatment. \nSTI data may be collected and reported from different HIV",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a recommended minimum dataset for monitoring STIs in HIV programmes, covering visit dates, syndromic or laboratory diagnoses, tests and samples, confirmatory results and treatment prescribed and dispensed, noting the need for clear case definitions where treatment is symptom-based.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-113",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority indicators for STIs",
      "pageStart": 199,
      "pageEnd": 201,
      "target": "../sections/sec-113-423-priority-indicators-for-stis.md",
      "narrative": null,
      "content": "Ref. no.\nShort name\nIndicator definition\nNumerator\nDenominator\nSTI.1\n(NEW)\nSyphilis testing \ncoverage \n% of people tested \nfor syphilis during the \nreporting period \nNumber of people \ntested for syphilis \nduring the reporting \nperiod \nNumber of people \nattending HIV \ntreatment or \nprevention services \nduring the reporting \nperioda \nSTI.2\n(NEW)\nSyphilis test \npositivity \n% of people who \ntested positive for \nsyphilis during the \nreporting period\nNumber of people \nwho tested positive \nfor syphilis during \nthe reporting period \n(tested positive on \nboth nontreponemal \nand treponemal \ntests or tes",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of priority STI indicators for HIV programmes, such as syphilis testing coverage, positivity and treatment coverage and treatment of symptomatic STIs, with numerators, denominators and notes on disaggregation and country-specific treatment rules.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-114",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Viral hepatitis",
      "pageStart": 201,
      "pageEnd": 201,
      "target": "../sections/sec-114-43-viral-hepatitis.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-115",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background and rationale",
      "pageStart": 201,
      "pageEnd": 203,
      "target": "../sections/sec-115-431-background-and-rationale.md",
      "narrative": null,
      "content": "Viral hepatitis burden\nHepatitis B and C viral infections account for a significant global disease burden and high \nmortality from cirrhosis and hepatocellular cancer. In 2019 WHO estimated that, worldwide, \n296 million people were living with chronic HBV infection and 58 million people, with HCV \ninfection, together causing over one million deaths annually (13). The greatest burden of viral \nhepatitis infection is concentrated by geography and population, with 80% of the global \nburden of HCV infection in the 10 most severely affected countries (13). People in economically \ndisadvantaged regi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the global burden of hepatitis B and C, with 296 million and 58 million people infected in 2019 and over a million deaths a year, concentrated in certain countries and populations such as people who inject drugs. It explains shared prevention approaches with HIV, elimination strategies and the need for person-centred monitoring of the hepatitis care and cure cascade.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p202",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 202,
      "pageEnd": 202,
      "target": "../figures/vfig-p202.webp",
      "narrative": "draft",
      "content": "Fig. 4.2, four world choropleth maps of the prevalence of hepatitis B surface antigen (HBsAg) among people living with HIV in (A) the general population, (B) people who inject drugs, (C) men who have sex with men and (D) other populations at elevated risk of HIV. Countries are shaded by prevalence category (<5%, 5 to <15%, 15 to <50%, ≥50%) or marked as missing; most countries have missing data in each map, with data mainly from parts of Africa, Asia and the Americas. Source: Platt et al., 2020.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-116",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Minimum dataset for viral hepatitis",
      "pageStart": 203,
      "pageEnd": 204,
      "target": "../sections/sec-116-432-minimum-dataset-for-viral-hepatitis.md",
      "narrative": null,
      "content": "Table 4.3 presents a minimum set of data elements specifically on testing and treatment of \nviral hepatitis to be routinely collected and reported in HIV programmes. Viral hepatitis data \nmay be collected and reported from different HIV programmes, that is, HIV prevention services, \nincluding community outreach programmes, HIV testing, care and treatment clinics and key \npopulation programmes. Because viral hepatitis data will include people living with HIV as well \nas individuals receiving HIV testing or prevention services who may have either unknown HIV \nstatus or test HIV-negative, disaggr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a minimum dataset for viral hepatitis in HIV programmes, covering HBV and HCV test dates and results, treatment start and regimen and HCV cure testing, stressing disaggregation by HIV status.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-117",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority indicators for viral hepatitis",
      "pageStart": 204,
      "pageEnd": 206,
      "target": "../sections/sec-117-433-priority-indicators-for-viral-hepatitis.md",
      "narrative": null,
      "content": "Table 4.4 presents the proposed HBV and HCV indicators to be collected and reported \nroutinely within all HIV programmes. \nThe indicators are based on the 10 core indicators of the M&E framework for viral hepatitis (40) \nas well as the targets for the elimination of viral hepatitis (41). Also, data collected from these \nindicators complement other requirements for Member States to report to WHO. These include \nthe Global AIDS Monitoring (GAM) and the Global Reporting System for Hepatitis (GRSH) as \nwell as the indicators for validation of viral hepatitis elimination. \nTable 4.4 Priority indica",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of priority viral hepatitis indicators for HIV programmes, including HBV and HCV testing coverage, positivity, treatment and cure, aligned with WHO's hepatitis monitoring framework and global reporting systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.3. Recommended minimum dataset for viral hepatitis",
      "pageStart": 204,
      "pageEnd": 204,
      "target": "../tables/table-4-3.csv",
      "narrative": "draft",
      "content": "The table lists the minimum data elements recommended for recording viral hepatitis (HBV and HCV) information in HIV programmes, grouped by topic area: testing and diagnosis, treatment initiation and continuation, and monitoring of treatment effectiveness.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p206",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 206,
      "pageEnd": 206,
      "target": "../figures/vfig-p206.webp",
      "narrative": "draft",
      "content": "Fig. 4.3, four world choropleth maps of the HIV-attributable fraction in cervical cancer in 2020 for age groups ≤34, 35–44, 45–54 and ≥55 years. Countries are shaded by population attributable fraction (0 to <10, 10 to <20, 20 to <40, 40 to <80, ≥80%, or no data). Most of the world is in the lowest category; the highest fractions are concentrated in southern and eastern Africa, and the areas with higher fractions shrink with increasing age. Source: Ibrahim Khalil et al., 2022.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-118",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cervical cancer",
      "pageStart": 206,
      "pageEnd": 206,
      "target": "../sections/sec-118-44-cervical-cancer.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-119",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background and rationale",
      "pageStart": 206,
      "pageEnd": 208,
      "target": "../sections/sec-119-441-background-and-rationale.md",
      "narrative": null,
      "content": "Women living with HIV have a six-fold higher risk of cervical cancer than women without \nHIV (6), and cervical cancer is classified as an AIDS-defining condition (42). This higher risk \nstarts with an increased risk of acquiring HPV infection, lower chances of regression of pre-\ncancerous lesions, more rapid progression to cancer and higher rates of recurrence following \ntreatment (43-45). ART has led to steep declines in AIDS-related mortality and has increased \nlife expectancy, with over 19 million women estimated to be living with HIV worldwide in \n2019 (46). The proportion of women living",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that cervical cancer risk is six times higher in women living with HIV, with faster progression and more recurrence, and that the HIV-attributable fraction exceeds 40% in parts of southern Africa. It calls for integrated services and restates WHO's screening strategy for women living with HIV from age 25 every 3 to 5 years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-120",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Minimum dataset for cervical cancer",
      "pageStart": 208,
      "pageEnd": 210,
      "target": "../sections/sec-120-442-minimum-dataset-for-cervical-cancer.md",
      "narrative": null,
      "content": "screening and treatment among women living with HIV\nArea\nData element\nDetails\nHPV vaccination\nAge at last HPV vaccine dose received\nNumber of last dose (1, 2 or 3)a \nPrimary screening\nCervical cancer screening test date\nLifetime screening test number \nFirst in lifetime, second in lifetime, etc. \nScreening test used \nHPV DNA testing (including genotyping \nwhere done), visual inspection with \nacetic acid, cytology, other\nScreening test result \nDescription of test results will depend \non the screening test used (for \nexample, positive/negative or high-risk \ntype positive for HPV DNA testing, etc.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A minimum dataset for cervical cancer screening and treatment among women living with HIV, covering HPV vaccination, primary and triage testing, pre-cancer treatment and follow-up, invasive cancer treatment and death. It notes that screening should also be offered to transgender men and other people with a cervix.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-121",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority indicators for cervical cancer",
      "pageStart": 210,
      "pageEnd": 212,
      "target": "../sections/sec-121-443-priority-indicators-for-cervical-cancer.md",
      "narrative": null,
      "content": "The four priority indicators in Table 4.6 were selected based on their importance for measuring \nprogrammatic progress in increasing cervical screening and treatment for women living with \nHIV (47). These indicators are aligned with WHO’s guideline for screening and treatment of \ncervical pre-cancerous lesions for cervical cancer prevention (9), the noncommunicable disease \nprimary care facility-based patient and programme monitoring framework and indicators \non cervical cancer screening and the Global strategy to accelerate the elimination of cervical \ncancer as a public health problem (47).",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents four priority indicators for cervical cancer screening and treatment among women living with HIV, aligned with WHO screening guidance and the elimination strategy, with age disaggregation from 20 and inclusive, confidential gender categories.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.6. Priority indicators for cervical cancer screening and treatment among womenᵃ living with HIV",
      "pageStart": 211,
      "pageEnd": 211,
      "target": "../tables/table-4-6.csv",
      "narrative": "draft",
      "content": "The table defines four priority indicators (CCA.1–CCA.4) for cervical cancer screening and treatment among women living with HIV, giving for each its reference number, short name, definition, numerator and denominator. CCA.1 and CCA.2 are marked as core indicators.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-122",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 212,
      "pageEnd": 217,
      "target": "../sections/sec-122-references.md",
      "narrative": null,
      "content": "1.\t Tracking universal health coverage: 2021 Global Monitoring Report (Conference edition). \nGeneva and Washington (DC): World Health Organization and World Bank; 2021 (https://\nwww.who.int/publications/i/item/9789240040618, accessed 23 June 2022).\n2.\t Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and \npractice: the contribution of other sexually transmitted diseases to sexual transmission of \nHIV infection. Sex Transm Infect. 1999;75:3-17. doi: 10.1136/sti.75.1.3\n3.\t Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F et al. Age-specific \nburde",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for chapter 4, citing mainly studies and WHO strategies on STIs, viral hepatitis, HPV and cervical cancer in people living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-123",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 5 – Harnessing the strength of routine data for HIV surveillance",
      "pageStart": 217,
      "pageEnd": 218,
      "target": "../sections/sec-123-chapter-5-harnessing-the-strength-of-routine-dat.md",
      "narrative": null,
      "content": "HARNESSING THE \nSTRENGTH OF ROUTINE \nDATA FOR HIV SURVEILLANCE\n5\nKey recommendations\b\n188\n5.1\t Introduction\b\n189\n5.1.1 Harnessing routine data to track the epidemic and guide the response \b\n189\n5.1.2 Using data from routine HIV surveillance systems \b\n193\n5.2\t Methods for estimating HIV incidence and prevalence using routine data\b\n194\n5.2.1 CD4/AIDS back-calculation\b\n194\n5.2.2 Retesting\b\n198\n5.2.3 Recency assays\b\n201\n5.2.4 Routine antenatal HIV testing\b\n204\n5.2.5 Age-specific HIV prevalence\b\n208\n5.2.6 Phylogenetics\b\n209\n5.2.7 Inclusion of routine data in modelling\b\n211\n5.3\t Minimum dataset requ",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The opening page and contents of chapter 5, on using routine data for HIV surveillance, including methods for estimating incidence and prevalence, a minimum dataset and data quality needs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-124",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key recommendations",
      "pageStart": 218,
      "pageEnd": 219,
      "target": "../sections/sec-124-key-recommendations.md",
      "narrative": null,
      "content": "NEW   \u00071. \u0007It is recommended that national health information systems include and \nstrengthen individual-level HIV surveillance that:  \n\t\na) \u0007routinely links individual data on HIV prevention, diagnosis and treatment \nover time as people move between facilities and locations \n\t\nb) \u0007provides granular, subnational strategic information for public health action.\nNEW   \u00072. \u0007Collection of a minimum dataset of routine clinical health information \nis recommended for national surveillance to monitor and guide the HIV \nresponse and support measurement of incidence: \n\t\na) \u0007Methods using person-centred d",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists five new key recommendations for chapter 5: individual-level HIV surveillance linking data over time, a minimum routine clinical dataset to support incidence measurement, CD4 testing at diagnosis, reporting mortality and causes of death, and stronger electronic case surveillance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-125",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 219,
      "pageEnd": 219,
      "target": "../sections/sec-125-51-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-126",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Harnessing routine data to track the epidemic and guide the response",
      "pageStart": 219,
      "pageEnd": 223,
      "target": "../sections/sec-126-511-harnessing-routine-data-to-track-the-epidemi.md",
      "narrative": null,
      "content": "the response \nSeveral indicators are important for tracking the course of the HIV epidemic and progress of \nthe response. Impact indicators that measure trends in HIV incidence, all-cause and AIDS-\nrelated mortality among persons with HIV, and outcomes such as ART coverage and viral \nsuppression have been critical in identifying service gaps and for prioritizing commitments \nof resources and services (1, 2). Typically, these indicators come from a mix of nationally \nrepresentative surveys and programmatic data on the number of individuals who have received \nservices, which can be synthesized w",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why tracking HIV incidence, prevalence and mortality matters for guiding the response and meeting global targets, and how routine person-centred data can complement other sources. It describes common measurement methods, including population-based and bio-behavioural surveys, cohort studies and mathematical models such as Spectrum, with their strengths and limits. It also addresses mortality measurement. It ends by advising against routinely collecting key population information where safety is a concern and suggesting triangulation of programme and survey data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-127",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Using data from routine HIV surveillance systems",
      "pageStart": 223,
      "pageEnd": 224,
      "target": "../sections/sec-127-512-using-data-from-routine-hiv-surveillance-sys.md",
      "narrative": null,
      "content": "Most countries manage a complex system of individual patient-level data and summed \naggregated information based on these data. Patient information systems typically interface \n(directly, via interoperability, or indirectly, via manual data transfer) with laboratory and \npharmacy routine information systems to more efficiently capture essential information for use \nin routine cascade analyses as well as in data validation and quality assessments (28). Data \ncollected through person-centred monitoring may be aggregated at the facility level before \nbeing reported to higher levels of the health",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how countries combine individual patient-level and aggregated data, noting that manual aggregation limits flexible analysis and quality checks. It outlines what HIV case surveillance should capture and the rights-based framework, case definitions and data systems it requires.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-128",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods for estimating HIV incidence and prevalence using routine data",
      "pageStart": 224,
      "pageEnd": 224,
      "target": "../sections/sec-128-52-methods-for-estimating-hiv-incidence-and-prev.md",
      "narrative": null,
      "content": "using routine data\nTo promote sustainable and efficient surveillance platforms to guide HIV prevention, testing \nand treatment efforts, it is essential to strengthen the demand, supply, analysis and use of \nroutine HIV programme or service data. To demonstrate the utility of routine programmatic \nsurveillance data to guide the global, national and subnational response, and to inform \nmodels such as Spectrum, the methods in this guidance focus on approaches to measuring \nHIV incidence and prevalence. These methods utilize individual-level data (either paper-based \nor, preferably, electronic) th",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces methods for estimating HIV incidence and prevalence from routinely collected individual-level programme data to inform models such as Spectrum, including seroconversion rates as a proxy for incidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-129",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CD4/AIDS back-calculation",
      "pageStart": 224,
      "pageEnd": 228,
      "target": "../sections/sec-129-521-cd4aids-back-calculation.md",
      "narrative": null,
      "content": "2.\t retesting\n3.\t recency testing\n4.\troutine antenatal HIV testing\n5.\t age-specific HIV prevalence \n6.\tphylogenetics\n7.\t inclusion of routine data in modelling.\n5.2.1 CD4/AIDS back-calculation\nBackground\nBack-calculation is a widely used method to estimate the number of newly acquired HIV \ninfections over time, or HIV incidence, from observed longitudinal data on HIV or AIDS \ndiagnoses (19-21, 33). The principle underlying back-calculation is that, if the evolution of a \nbiomarker (for instance, CD4 cell counts) during untreated HIV infection is well characterized, \nlevels of that biomarker at",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists seven methods for using routine data to estimate HIV incidence and explains the first, CD4/AIDS back-calculation, which infers time since infection from CD4 levels at diagnosis. It describes how missing CD4 values can be imputed and why the method is often the only option in concentrated epidemics. A Brazilian example shows the approach applied to national surveillance data, with a map of new HIV cases by municipality in 2019.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p227",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 227,
      "pageEnd": 227,
      "target": "../figures/vfig-p227.webp",
      "narrative": "draft",
      "content": "Fig. 5.1, within Box 5.1, a proportional-symbol map of Brazil showing the number of new HIV cases by municipality in 2019, with dot sizes for categories from 0–0 up to 1000–2081 cases. The largest clusters of dots are along the south-eastern and southern coast and in the north-east, with a large dot in the Amazon region and sparse dots in the interior. Source: Ministry of Health, Brazil.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p228",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 228,
      "pageEnd": 228,
      "target": "../figures/vfig-p228.webp",
      "narrative": "draft",
      "content": "Fig. 5.2, three linked 100% stacked bars showing HIV test positivity by prior testing status in Western Cape Province, South Africa. Of those presenting for testing, 8938 (78.8%) were HIV-negative and 2399 (21.2%) HIV-positive from all sources. Of all positives, 1184 (49.4%) self-reported HIV-positive and were not retested, 623 (24.4%) were retested HIV-positive and 592 (24.7%) were newly diagnosed. Of those testing positive, 592 (48.7%) were newly diagnosed, 308 (25.3%) retested in spite of self-reporting prior HIV and 315 (25.9%) were retested without self-reporting prior knowledge of status. Source: Jacob et al., 2020.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-130",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Retesting",
      "pageStart": 228,
      "pageEnd": 231,
      "target": "../sections/sec-130-522-retesting.md",
      "narrative": null,
      "content": "Background\nRetesting for HIV can play an important part in sustaining prevention activities, particularly \nin high burden settings, as it provides opportunities to engage or re-engage people testing \nHIV-negative (39) and facilitates re-linkage to HIV care among those who are HIV-positive (40). \nFrequent retesting among priority groups such as key populations, for whom testing at least \nannually is recommended (41), can help promote earlier diagnosis among people who have \nacquired HIV since their last negative test. \nThe decision to retest has been reported as linked to a person’s awareness o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how HIV retesting supports prevention and re-linkage to care, the factors linked to retesting, and why some people who already know they are positive retest. It discusses how longitudinal testing data can identify duplicate diagnoses and support a cyclical care cascade. It describes using seroconversions in routine testing data to estimate incidence, the biases involved, and a study where behavioural and serological estimates agreed closely.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-131",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Recency assays",
      "pageStart": 231,
      "pageEnd": 234,
      "target": "../sections/sec-131-523-recency-assays.md",
      "narrative": null,
      "content": "A primary outcome of interest in routine surveillance is HIV status. Beyond knowing whether \na person is either HIV-negative or positive, it can also be useful to ascertain, among those \ntesting HIV-positive, whether they were likely to have been infected recently. In population-\nbased surveys, recency assays can be used to accurately estimate HIV incidence. In routine \nprogrammatic settings the individuals who attend HIV testing do so in a non-random manner \n(depending on such motivations as their perceived risk for HIV) and are not representative of \nthe population. Therefore, recency testin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how recency assays can estimate incidence in population surveys, but in routine programmes are best applied to groups tested for reasons unrelated to risk, such as antenatal clients, and not used for individual clinical management. It discusses biases from non-random testing and how testing history, viral load and ART exposure improve classification of recent infections. It concludes that recency data on distribution and trends should be compared with other surveillance methods for estimating incidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-132",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Routine antenatal HIV testing",
      "pageStart": 234,
      "pageEnd": 238,
      "target": "../sections/sec-132-524-routine-antenatal-hiv-testing.md",
      "narrative": null,
      "content": "Background\nEarly in the global HIV/AIDS pandemic, pregnant women attending ANC were identified as an \nideal sentinel population through which to monitor population-wide HIV trends (77) because \nwomen become pregnant and present for health screening at ANC for reasons unrelated to HIV \nrisk factors or disease. Therefore, measures of HIV prevalence among pregnant women were \nconsidered more representative of population-wide HIV levels than HIV prevalence among \nother sentinel populations such as, for example, clients at STI clinics or hospital inpatients, \nwho are disproportionately affected by",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the long use of pregnant women at antenatal clinics as a sentinel population for HIV trends and the shift to near-universal routine antenatal testing. It discusses how changes in testing or reporting practices can distort trends and why antenatal prevalence differs systematically from that of the general population. It lists conditions for routine antenatal data to be reliable for surveillance, such as high attendance and testing coverage and using only the first test per pregnancy. It also considers incidence during pregnancy and the postpartum period.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-133",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Age-specific HIV prevalence",
      "pageStart": 238,
      "pageEnd": 239,
      "target": "../sections/sec-133-525-age-specific-hiv-prevalence.md",
      "narrative": null,
      "content": "Demographic methods have been developed to use age-specific cross-sectional HIV prevalence \ndata, and, therefore, changes in HIV prevalence by age, to better understand HIV incidence \n(6, 99). Methods previously used for estimating HIV incidence from age-specific prevalence \ndata include cumulative incidence methods and survival methods (99). As several assumptions \n(described below) are required to draw conclusions using these methods (100), they are no \nlonger suggested as a means of estimating or interpreting HIV incidence. They may still provide \ninsights into the plausible limits of HIV i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that methods estimating HIV incidence from age-specific prevalence rely on strong assumptions and are no longer recommended, though they may still indicate plausible limits. It explains the assumptions involved and includes a figure of people living with HIV by timing of infection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p239",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 239,
      "pageEnd": 239,
      "target": "../figures/vfig-p239.webp",
      "narrative": "draft",
      "content": "Fig. 5.3, a stacked bar chart of the number of adolescents aged 15–19 living with HIV globally, 2000–2021, by timing of infection (perinatally infected vs. infected after age 15). Totals stay around 1.0–1.15 million throughout. The perinatally infected share rises steadily from under 50 000 in 2000 to about 650 000 by 2018–2021, while the number infected after age 15 falls correspondingly. Source: UNAIDS epidemiological estimates, 2022.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-134",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Phylogenetics",
      "pageStart": 239,
      "pageEnd": 241,
      "target": "../sections/sec-134-526-phylogenetics.md",
      "narrative": null,
      "content": "In recent years the use of molecular epidemiology to reconstruct viral transmission networks \nhas been recognized widely as a tool for successful interventions to curtail outbreaks of \ninfection. This approach forms an explicit part of the Ending the Epidemic programme in the \nUSA (https://www.cdc.gov/endhiv/index.html). Recent studies published by the Centers for \nDisease Control and Prevention (CDC) demonstrate the effectiveness of sequence analysis \nfor outbreak monitoring and for the identification of clusters representing recent and rapid \ntransmissions (103, 104). Where HIV Drug Resistan",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how phylogenetic analysis of HIV sequences, for instance from drug resistance surveillance, can reveal transmission clusters and recent rapid transmission, as used in the US Ending the Epidemic programme. It notes limited feasibility in resource-limited settings and illustrates how a cluster grows between samples taken two years apart.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-135",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Inclusion of routine data in modelling",
      "pageStart": 241,
      "pageEnd": 243,
      "target": "../sections/sec-135-527-inclusion-of-routine-data-in-modelling.md",
      "narrative": null,
      "content": "Using routine data for estimates of HIV incidence and prevalence has several advantages. As \nthese data are routinely collected, few extra resources are needed for measuring incidence \nand prevalence. Another important advantage of routine data is that estimates can easily \nbe updated over time as additional years of data become available. In settings with HIV \nepidemics concentrated in key populations, use of routine data can be more challenging due \nto non-disclosure of HIV risk factors by key population clients. In these cases key population \nsurvey data can be used. Where data are availabl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the advantages of using routine data in modelling HIV incidence and prevalence, such as low cost and easy updating, and the difficulties in key population epidemics. It stresses engaging key population organizations and describes data cleaning and imputation methods for missing values, favouring multiple imputation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-136",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Minimum dataset required for estimating HIV incidence and prevalence",
      "pageStart": 243,
      "pageEnd": 246,
      "target": "../sections/sec-136-53-minimum-dataset-required-for-estimating-hiv-i.md",
      "narrative": null,
      "content": "incidence and prevalence \nNational routine HIV surveillance systems will need to collect a minimum standardized set \nof reportable data elements (Table 5.1) in order to estimate HIV incidence and prevalence \nusing the methods described above. These data elements include HIV diagnosis date and all \nimmunological testing results such as CD4 count and viral load for individuals newly diagnosed \nwith HIV, as WHO clinical guidelines recommend (112). Surveillance data on HIV case reports \nshould link to databases that may contain laboratory information such as CD4 and viral load \ntest results. At a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that national surveillance systems need a standardized minimum set of reportable data elements, such as diagnosis date, CD4 count and viral load, to estimate incidence and prevalence. It recommends linking case reports to laboratory data and collecting CD4 at diagnosis as a minimum. Table 5.1 lists the required elements, with notes on recency testing and use of electronic records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-137",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data quality needs for the use of routine data",
      "pageStart": 246,
      "pageEnd": 247,
      "target": "../sections/sec-137-54-data-quality-needs-for-the-use-of-routine-dat.md",
      "narrative": null,
      "content": "While routine facility data provide a powerful tool for granular, timely analyses, in different \nsettings integrated data systems with high coverage are at different stages of maturation. Still, \nin many of these same settings, some form of HIV case reporting and surveillance has been in \nplace for years, either through paper or electronic systems. The quality of routine data \n(including reliability, completeness, accuracy and timeliness) depends upon how well \ninformation is captured by HIS and health service providers, and is cleaned and reviewed by \ndata managers. For example, failure of so",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that routine data quality depends on how well information is captured and cleaned, and that inconsistent reporting can be mistaken for real changes in coverage. It calls for a culture of data quality assessment and use so that routine facility data can sustainably monitor incidence, prevalence and the HIV response.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-138",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 247,
      "pageEnd": 255,
      "target": "../sections/sec-138-references.md",
      "narrative": null,
      "content": "1.\t\nConsolidated HIV strategic information guidelines: driving impact through programme \nmonitoring and management. Geneva: World Health Organization; 2020 (https://www.\nwho.int/publications/i/item/9789240000735, accessed 2 April 2022).\n2.\t\nGlobal AIDS Update 2021. Confronting inequalities: lessons for pandemic responses \nfrom 40 years of AIDS. Geneva: United Nations Joint Programme on HIV/AIDS (UNAIDS) \n(https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, \naccessed 23 June 2022).\n3.\t\nBrown K, Williams DB, Kinchen S, Saito S, Radin E, Patel H et al. Status of HIV epidem",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the chapter on routine data for HIV surveillance, citing WHO and UNAIDS guidance, population surveys, and studies on back-calculation, recency testing, antenatal surveillance, phylogenetics and modelling tools.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-139",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 6 – Digital health data",
      "pageStart": 255,
      "pageEnd": 256,
      "target": "../sections/sec-139-chapter-6-digital-health-data.md",
      "narrative": null,
      "content": "DIGITAL HEALTH DATA\n6\nKey recommendations\b\n226\n6.1\t Introduction\b\n227\n6.1.1 Overview\b\n227\n6.2\t Interoperability\b\n232\n6.2.1 Overview\b\n232\n6.2.2 Organizational interoperability (governance)\b\n234\n6.2.3 Legal interoperability\b\n236\n6.2.4 Technical interoperability\b\n237\n6.2.5 Data use and exchange\b\n238\n6.3\t Unique identifiers\b\n239\n6.3.1 Overview\b\n239\n6.3.2 Development path for UIDs\b\n241\n6.3.3 System architecture and methods of UID\b\n247\n6.4\t Privacy, security, data access and control\b\n252\n6.4.1 Overview\b\n252\n6.4.2 Situation analysis to assess privacy, confidentiality and security \nof a digital system",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The contents listing for Chapter 6 on digital health data, covering interoperability, unique identifiers, and privacy, security and data access.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-140",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key recommendations",
      "pageStart": 256,
      "pageEnd": 257,
      "target": "../sections/sec-140-key-recommendations.md",
      "narrative": null,
      "content": "Interoperability \nUPDATE\t\n1.\t\u0007Explicitly build in interoperability standards, data use rules and \nobligations and transparent data governance in digital health systems to \nallow the secure exchange and use of health data:\nUPDATE\t\n\t a)\t \u0007Use technical, organizational and legal interoperability standards \nto facilitate data governance and to smooth data exchange and use \nbetween health care sector partners. \nNEW\t\n\t b) \u0007Publish agreed-upon standards, rules, frameworks and conditions for \ndata use by health ministries, partners and civil society to improve \ntransparency, data sharing and use.\nUniq",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out updated and new recommendations on digital health data: building interoperability standards and transparent data governance, publishing data-use rules, and using anonymous unique identifiers to link a person's records across services. It also covers privacy, security and restricting access to personal data to authorized parties.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-141",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 257,
      "pageEnd": 257,
      "target": "../sections/sec-141-61-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-142",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview",
      "pageStart": 257,
      "pageEnd": 262,
      "target": "../sections/sec-142-611-overview.md",
      "narrative": null,
      "content": "The exponential growth in, and use of, health data necessitates systematic investment in \ndigital health care systems. Capitalizing on this growth in digital data in health care is a major \nopportunity for a country’s health care services to work in concert to improve health outcomes \nof all individuals. Health care systems are complex, involving many different individuals, \nfacilities, conditions and treatments, and the data used in health care are often personal and \nsensitive. Thus, the transition from paper-based systems to digitization of health data, the \nso-called “maturation pathway”,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the shift from paper to digital health data, describing its opportunities for better outcomes and its risks for privacy and individual rights, especially in HIV. It stresses that governance and a protective policy environment matter as much as technology, and notes that some aspects of care are hard to capture digitally. It discusses the digital divide that limits access to digital services. A case example from Malawi describes a digital platform for managing HIV programme performance that flags facilities with worrying trends.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-img-p262-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 262,
      "pageEnd": 262,
      "target": "../images/img-p262-1.webp",
      "narrative": "draft",
      "content": "Screenshot of the PALMS 'Sexually Transmitted Infections' dashboard for Blantyre district (Fig. 6.1). A map shows facilities as circles coloured by % new HIV positive (0–10%) in 2021 Q4, with circle size indicating total tested for HIV; a line chart of % new HIV positive by quarter, 2018 Q1 to 2022 Q2, stays around 4–6% except a spike to about 16% in 2019 Q4; and a table lists facilities by total clients (total 267 new HIV positive, 3.7%, of 7257 tested), with red flags against Ndirande Health Centre and Makhetha Clinic.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p262",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 262,
      "pageEnd": 262,
      "target": "../figures/vfig-p262.webp",
      "narrative": "draft",
      "content": "Fig. 6.1, within Box 6.3, a screenshot of the PALMS 'Sexually Transmitted Infections' dashboard showing HIV rates among STI clients in Blantyre district, Malawi. It combines a map of facilities with circles coloured by % new HIV positive (0–10%) in 2021 Q4, a line chart of % new HIV positive by quarter from 2018 Q1 to 2022 Q2 that stays around 4–6% apart from a spike to about 16% in 2019 Q4, and a table of facilities by total clients (total 267 new HIV positive, 3.7%, of 7257 tested), with red flags against two facilities. Developed by Cooper/Smith with Georgetown University through the Blantyre Prevention Strategy.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-143",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interoperability",
      "pageStart": 262,
      "pageEnd": 262,
      "target": "../sections/sec-143-62-interoperability.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-144",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview",
      "pageStart": 262,
      "pageEnd": 264,
      "target": "../sections/sec-144-621-overview.md",
      "narrative": null,
      "content": "In order for data to be used effectively, data needs to be exchanged between, and understood \nby, the many different stakeholders in the health care system. Interoperability enables this \nexchange and a common understanding of the data. This section outlines the different types \nof interoperability, the benefits of an interoperable health care system and considerations for \nprogressive and sustainable adoption of interoperability within health care data systems. \nInteroperability is the ability of different applications to access, exchange, integrate and \nuse data in a coordinated manner, thro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines interoperability as the ability of systems to access, exchange and use data across organizations and boundaries, and outlines organizational, legal and technical types. It describes benefits at the point of care, within and between facilities, such as reducing loss to follow-up and improving supply decisions, and the value of publishing standards and business processes. It notes that full interoperability is hard to achieve and needs incentives at technical and legal levels.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-145",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Organizational interoperability (governance)",
      "pageStart": 264,
      "pageEnd": 266,
      "target": "../sections/sec-145-622-organizational-interoperability-governance.md",
      "narrative": null,
      "content": "To maximize the benefits from investments in digital systems, countries need to ensure that \nthe systems follow and maintain interoperability standards. The health care system is complex, \ninvolving many stakeholders working in overlapping areas. National digitization strategies need \nto acknowledge this complexity and convene stakeholders to develop data systems that reflect \nand benefit the different participating public and private systems. \nOrganizational interoperability concerns data use and exchange between different \norganizations working in digital health. Organizational interoperabil",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains organizational interoperability as aligning the goals and relationships of organizations so data can be exchanged, and describes supporting measures such as national strategy documents. It illustrates business process mapping with an example workflow for HIV testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p266",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 266,
      "pageEnd": 266,
      "target": "../figures/vfig-p266.webp",
      "narrative": "draft",
      "content": "Fig. 6.2, within Box 6.4, an abridged swimlane business process diagram for HIV testing, with lanes for the client and the trained lay provider at the health facility/community. After registration, the provider determines the reason for visit and checks for signs of serious illness (referral if yes), then within a post-test package collects client details, takes vital signs, provides pre-test information, tests for HIV using the testing algorithm, provides post-test counselling and determines recommended services. Depending on the HIV test result, positive leads to counselling on ART and disclosure and partner services, while negative or inconclusive leads to a retest decision and scheduling a retest; the client makes an informed decision on care. Source: WHO, 2022.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-146",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Legal interoperability",
      "pageStart": 266,
      "pageEnd": 267,
      "target": "../sections/sec-146-623-legal-interoperability.md",
      "narrative": null,
      "content": "Legal interoperability aims to enforce organizational interoperability and to ensure that \nthere are no legal barriers that might prevent or restrict the sharing or understanding of \ndata between organizations working across different regions, countries or jurisdictions. \nIt also lays out the rules and obligations for data sharing and use within the health system, \nincluding sharing a minimum data set with the health ministry. Legal hurdles should not \nhinder data sharing or cooperation between organizations working in health care, where the \nbenefits of such cooperation will improve patient o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains legal interoperability, which removes legal barriers to data sharing and sets rules on ownership, protection, privacy, individual access and storage. It continues the HIV testing business process diagram.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-147",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Technical interoperability",
      "pageStart": 267,
      "pageEnd": 268,
      "target": "../sections/sec-147-624-technical-interoperability.md",
      "narrative": null,
      "content": "Technical interoperability encompasses a range of areas. Semantic interoperability covers \nthe standards for the meaning of data elements and relationships between them. Syntactic \nstandards specify data formats, or the “grammar” of the data to be shared. Technical \ninteroperability also covers standards that define protocols for data exchange that ensure \nsecurity and privacy. \nConventions for technical interoperability are usually defined via an international “standard”, \nwhich is developed and maintained by international organizations such as the International \nOrganization for Standardizat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains technical interoperability, covering semantic and syntactic standards and secure exchange protocols developed by bodies such as ISO, HL7 and SNOMED International. It uses everyday product standards as an analogy and names JSON and XML as common data formats.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-148",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data use and exchange",
      "pageStart": 268,
      "pageEnd": 269,
      "target": "../sections/sec-148-625-data-use-and-exchange.md",
      "narrative": null,
      "content": "It is important to be able to share data between facilities and between systems to provide \ncontinuous, person-centred services when, for example, an individual moves to a different \nlocation and clinical setting. Fast Health care Interoperability Resources (FHIR, pronounced \n“fire”) is a popular specification for data exchange maintained by HL7 (36). The FHIR \nspecification is composed of 1) definitions of data models commonly used in a health care \nsetting (termed “resources”), 2) data formats (for example, JSON and XML) and 3) protocols \nfor exchanging data (for example, in the case of FHIR",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the need to share health data between facilities and systems and describes the HL7 FHIR specification, its resources, formats and exchange protocols and why it is popular. Box 6.5 uses WHO's digital documentation of COVID-19 certificates to illustrate technical, semantic and governance aspects of interoperability.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-149",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Unique identifiers",
      "pageStart": 269,
      "pageEnd": 269,
      "target": "../sections/sec-149-63-unique-identifiers.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-150",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview",
      "pageStart": 269,
      "pageEnd": 271,
      "target": "../sections/sec-150-631-overview.md",
      "narrative": null,
      "content": "UIDs are numeric or alphanumeric codes that support individuals to identify themselves \nwhen accessing a variety of health services and support health workers in linking relevant \nhealth information when providing services.1 The UID should be anonymized and used in \nindividual-level health data systems. A well-designed UID is free of any personally identifiable \ninformation (that is, “content-free” unique identifiers2). Information such as location, place of \nissue or date of birth should not be part of the UID, as these may be used to identify individuals \nand, thus, breach individual privacy",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes unique identifiers (UIDs) that let people be recognised across HIV and other health services, stressing that they should be content-free and hold no personal details such as birth date or location. It outlines their benefits for linking records and efficiency, and the security and confidentiality risks they pose. The section closes by stating that sensitive details such as sexual orientation should not be collected unless clinically relevant, and that relevant clinical information can be kept in secure records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-151",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Development path for UIDs",
      "pageStart": 271,
      "pageEnd": 277,
      "target": "../sections/sec-151-632-development-path-for-uids.md",
      "narrative": null,
      "content": "Implementation of UIDs should take place in a step-wise fashion, reflecting country context. \nThe following steps are suggested:\n1.\t Situation analysis. Countries should conduct a situation analysis that reviews current \npolicies, data sources and systems and identifies incremental improvements, costs, \nrisks and benefits. This analysis should be tailored to the country context and involve \nthe participation of people who will be using the system for programmatic decisions \n(see Situation analysis, below). \n2.\t Data security. The next step is to invest in improved security, which includes inve",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends a step-wise path for introducing health UIDs, moving from situation analysis through data security and data use to programme improvement and sustainability. It details what the situation analysis should cover, including existing identifiers, data systems and capacities, and privacy and security laws and policies. It also covers costing benefits, maturity stages for technical components and integrating HIV monitoring into a national UID system. The section ends by stressing planning for policies, maintenance, hardware, software, staff and analytical capacity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-vfig-p273",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 273,
      "pageEnd": 273,
      "target": "../figures/vfig-p273.webp",
      "narrative": "draft",
      "content": "Fig. 6.3, a flow diagram of the broad stages and transitions of the maturation pathway for UIDs: name-based identifiers, then unique identifiers at select facilities (early transition), then unique identifiers widespread (middle), then data linked by UID across services, facilities and locations (advanced).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-152",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "System architecture and methods of UID",
      "pageStart": 277,
      "pageEnd": 282,
      "target": "../sections/sec-152-633-system-architecture-and-methods-of-uid.md",
      "narrative": null,
      "content": "Technical resources\nThis section presents the basic components of system architecture and the UID. This guidance \nshould enable programme managers to discuss the key considerations with the technical \nspecialists who will develop UID systems. It should be used in conjunction with documents that \nprovide more detailed technical information, including the following:\n•\t Standard guide for properties of a universal healthcare identifier (ASTM E-1714-07R13) (43);\n•\t Standard guide for implementation of a voluntary universal healthcare identification system \n(ASTM E-2553-07 (2013) (44);\n•\t Health in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines the system architecture for a UID system, pointing to ASTM, ISO and CEN technical standards for health identifiers. It describes three facility layers (paper only, reliable power, and network) and the equipment each needs, from data-entry workstations to central, regional or cloud registry servers, noting data-protection questions when data are stored abroad. It then covers interoperability and the technical components and attributes of a UID, ending with how registration and service data are captured and linked to commodity inventory systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-153",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Privacy, security, data access and control",
      "pageStart": 282,
      "pageEnd": 282,
      "target": "../sections/sec-153-64-privacy-security-data-access-and-control.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-154",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview",
      "pageStart": 282,
      "pageEnd": 284,
      "target": "../sections/sec-154-641-overview.md",
      "narrative": null,
      "content": "The increasing volume of digital data, along with the increasing use and transfer of these data \nand the concentration of data in centralized data warehouses, heightens both the risks and \nthe consequences of data breaches. Digital health care systems need to be designed from the \nstart and implemented with privacy, security and confidentiality in mind. These topics warrant \nserious scrutiny, not only to avoid breaches due to malicious or nefarious behaviour, but also to \navoid inadvertent breaches due to the design or implementation of the system that houses and \ntransfers the data. \nData use",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Warns that growing volumes of centralised digital health data raise the risk and impact of breaches, so systems must be designed for privacy, security and confidentiality from the outset. An example describes a real-time, person-centred electronic system for services to people who use drugs, with safeguards such as access levels, encryption and de-identified dashboards. Table 6.4 then sets out five types of health data, from personally identifiable to non-personal information.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-155",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Situation analysis to assess privacy, confidentiality and security of a digital system",
      "pageStart": 284,
      "pageEnd": 285,
      "target": "../sections/sec-155-642-situation-analysis-to-assess-privacy-confide.md",
      "narrative": null,
      "content": "of a digital system\nA situation analysis should be the first step in designing and implementing a digital system that \nensures security and the maintenance of confidentiality and privacy. UNAIDS has developed a \ntool for this purpose, The privacy, confidentiality and security assessment tool (56). \nThe tool assesses privacy, confidentiality and security through facilitation of a series of \ndiscussion workshops with key stakeholders, including detailed questionnaires for participants. \nThe tool was developed to determine how policies for privacy, confidentiality and security \nhave been develope",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends a situation analysis as the first step in securing a digital health system, using the UNAIDS privacy, confidentiality and security assessment tool run through stakeholder workshops. Table 6.5 lists sample questions on governance and policy and related areas at facility, data warehouse and policy levels.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-156",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data access and control",
      "pageStart": 285,
      "pageEnd": 288,
      "target": "../sections/sec-156-643-data-access-and-control.md",
      "narrative": null,
      "content": "Patients are the primary stakeholders in their own health. Accessing one’s personal health \ndata and legal assurance of its protection can build patients’ engagement with health systems \nand motivate individuals to see themselves as partners in their own health. Legislation is an \nimportant mechanism for ensuring that patients have access to, and control of, their own \nhealth data. These guidelines recommend that countries have rights-based, legal protections in \nplace for access to, and control of, such personal health information.\nTable 6.5 (continued) Questions used for situation analysis",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Argues that patients should have legally protected access to and control over their own health data and recommends rights-based legal protections. The continuation of Table 6.5 lists questions on access control, data release, transmission security and disposal. It then lists key legal provisions for personal health data, such as portability, revoking access, data protection officers, breach notification and penalties, and cites the EU GDPR principle of data minimisation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-157",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Indirect benefits",
      "pageStart": 288,
      "pageEnd": 289,
      "target": "../sections/sec-157-644-indirect-benefits.md",
      "narrative": null,
      "content": "Providing legal protections for the continuity of access and maintenance of rights of access \nto data has many secondary benefits that may drive other areas of digitization of the health \ncare system. As individuals move locations, maintenance of access also requires the movement \nof personal health care data across regions and facilities. This encourages initiatives easing \nthat process, such as the use of interoperability standards (section 6.2) and the adoption of \nwidely used, content-free UIDs (see section 6.3). Enabling patients to access their data creates \na demand for digital platform",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that legal protection of people's access to their health data brings indirect benefits, such as encouraging interoperability standards, content-free identifiers and digital platforms to hold personal records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-158",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 289,
      "pageEnd": 295,
      "target": "../sections/sec-158-references.md",
      "narrative": null,
      "content": "1.\t\nPrinciples for digital development [website]. 2018 (https://digitalprinciples.org/principles/, \naccessed 23 June 2022).\n2.\t\nThe State of the World’s Children 2017: children in a digital world New York: United \nNations Children’s Fund (UNICEF); 2017 (https://www.unicef.org/reports/state-worlds-\nchildren-2017, accessed 23 June 2022).\n3.\t\nWorld Development Report 2021: data for better lives. Washington (DC): World Bank; \n2021. p. 164, Chapter 5.\n4.\t\nDigital implementation investment guide (DIIG): integrating digital interventions into \nhealth programmes. Geneva: World Health Organization; 202",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the chapter on digital health data, citing WHO digital health guidance, digital adaptation kits, COVID-19 certificate specifications, technical standards and GDPR articles.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-159",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 7 – Strengthening data use from all sources",
      "pageStart": 295,
      "pageEnd": 296,
      "target": "../sections/sec-159-chapter-7-strengthening-data-use-from-all-source.md",
      "narrative": null,
      "content": "STRENGTHENING DATA USE \nFROM ALL SOURCES\n7\n7.1\t Introduction\b\n266\n7.1.1 A comprehensive data use framework\b\n266\n7.1.2 Sources of data on HIV and their use\b\n267\n7.2\t Measuring and improving the quality of person-centred care\b\n268\n7.2.1 Background and rationale\b\n268\n7.2.2 Measuring QOC\b\n269\n7.2.3 Community engagement in measuring QOC\b\n271\n7.2.4 A QOC framework for selecting indicators\b\n271\n7.2.5 Priority indicators\b\n273\n7.3\t Community-led monitoring\b\n275\n7.4\t Logistics management information systems\b\n277\n7.5\t Health facility assessments\b\n279\n7.6\t Civil registration and vital statistics\b\n280\n7.7",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The opening page of Chapter 7 on strengthening data use from all sources, listing its sections, including quality of care, community-led monitoring, logistics systems, surveys, modelling and data quality review.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-160",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 296,
      "pageEnd": 296,
      "target": "../sections/sec-160-71-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-161",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "A comprehensive data use framework",
      "pageStart": 296,
      "pageEnd": 297,
      "target": "../sections/sec-161-711-a-comprehensive-data-use-framework.md",
      "narrative": null,
      "content": "Incorporating data from multiple sources is essential to the ability to make a comprehensive \nassessment of programme performance. Data systems differ, however, due to differences \nin local infrastructure capacity, digital health governance and planning, and the resources \ninvested in building and maintaining systems. Therefore, as countries plan investments in their \ndata systems, it is important to take into account the strengths and limitations of each data \nsource for the interpretation and use of the information generated. \nA national HIV monitoring and evaluation plan or framework should",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Argues that a national HIV monitoring and evaluation framework should combine multiple data sources, each with strengths and limits, and map data elements to users and purposes. It lists the many ways HIV and related data can be collected and stresses simple recording and reporting. The section ends with points on community data, such as linking identifiers to avoid double counting between community and facility services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-162",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Sources of data on HIV and their use",
      "pageStart": 297,
      "pageEnd": 298,
      "target": "../sections/sec-162-712-sources-of-data-on-hiv-and-their-use.md",
      "narrative": null,
      "content": "In considering how best to collect key data on the HIV programme and response, efforts should \nbe made to review current monitoring systems, to better link the monitoring of related services \nsuch as those for STIs, TB, viral hepatitis and cervical cancer, and to include an integrated set \nof quality of care (QOC) indicators relevant for programme management. Evaluations or special \nsurveys can be considered when analyses require more data than those collected through \nroutine monitoring systems or when the routine monitoring system is not expected to yield \nreliable information.\nThe most comm",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the most common sources of HIV programme data, from routine health information and case surveillance to laboratory and logistics systems, vital statistics, population surveys, special studies and community-led monitoring. It also outlines what the rest of the chapter covers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-163",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Measuring and improving the quality of person-centred care",
      "pageStart": 298,
      "pageEnd": 298,
      "target": "../sections/sec-163-72-measuring-and-improving-the-quality-of-person.md",
      "narrative": null,
      "content": "person-centred care",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment of a section heading on measuring and improving the quality of person-centred care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-164",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background and rationale",
      "pageStart": 298,
      "pageEnd": 299,
      "target": "../sections/sec-164-721-background-and-rationale.md",
      "narrative": null,
      "content": "Each year poor-quality care contributes to 5.7–8.4 million deaths from all causes in low- and \nmiddle-income countries (LMICs), comprising 15% of total deaths in these countries (5). More \nlives are lost due to poor-quality care than to lack of access to health care (6). In addition \nto the tremendous loss of life, annual economic losses associated with poor quality care are \nenormous, exceeding US$ 6 trillion (6). People‘s trust in health systems can be severely eroded \nif they have repeated negative experiences with poor quality health services and/or unsafe care \nwhich leads to unnecessary,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the rationale for measuring quality of care, citing estimates that poor-quality care causes millions of deaths and huge economic losses in low- and middle-income countries. It argues that people receiving HIV services need high-quality care, that quality must be measured across health system levels, and that WHO quality definitions should be used locally.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-165",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Measuring QOC",
      "pageStart": 299,
      "pageEnd": 301,
      "target": "../sections/sec-165-722-measuring-qoc.md",
      "narrative": null,
      "content": "Ideally, QOC is measured through existing strategic information systems. Thus, QOC data \ndepend on the strength of national health management information systems. A health system’s \nframework for measuring QOC should:\n•\t support the national strategic direction for quality \n•\t clearly define what data should be collected from which sources \n•\t be cognizant of capacity for measurement \n•\t strategize how data will be contextualized by triangulation with other data sources\n•\t plan how data will be used to drive QI and impact (7). \nSince person-centred care emphasizes integrated care for HIV and r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how quality of HIV care should be measured mainly through existing information systems and routine data, with a framework that defines data sources, capacity, triangulation and use for improvement. It stresses capturing integrated, longitudinal care across service points, considering the diversity of clients and keeping data anonymised. The section also notes related services, such as palliative and psychosocial care, that should be considered when measuring quality.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-166",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Community engagement in measuring QOC",
      "pageStart": 301,
      "pageEnd": 301,
      "target": "../sections/sec-166-723-community-engagement-in-measuring-qoc.md",
      "narrative": null,
      "content": "The community plays an invaluable role in measuring QOC and holding all stakeholders \naccountable for offering high-quality care to all people seeking and using HIV services, \nincluding subpopulations such as key populations. Community stakeholders and community-led \norganizations, especially those involving specific subgroups, experience QOC first-hand and so \nmay be best equipped to identify what is important to these groups and what gaps in services \nor service quality particularly affect them. \nContributions from community stakeholders during the processes of defining QOC, collecting \ndata",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Highlights the role of communities and community-led organisations in defining and measuring quality of HIV care and holding stakeholders accountable, pointing to community-led monitoring as a complement to routine data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-167",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "A QOC framework for selecting indicators",
      "pageStart": 301,
      "pageEnd": 303,
      "target": "../sections/sec-167-724-a-qoc-framework-for-selecting-indicators.md",
      "narrative": null,
      "content": "A QOC measurement framework should encompass:\n•\t factors of greatest importance and concern to people accessing HIV prevention, testing, \ntreatment and related services at different stages of life; \n•\t multiple stakeholders engaged in the health care system, including physicians, provider \norganizations and patients or clients, and a review of the challenges and enablers they \nface in the provision of quality of care, along with measures of their performance (20);\n•\t validated measures and tools to capture data, even for person-centred measures where \nthe reference standard is self-reporting;",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes what a quality-of-care measurement framework should include, such as what matters most to service users, multiple stakeholders, validated tools, and clinical and patient-reported indicators of experience, perception, knowledge and outcomes. It introduces a person-centred indicator framework (Table 7.2) for selecting indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-168",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority indicators",
      "pageStart": 303,
      "pageEnd": 305,
      "target": "../sections/sec-168-725-priority-indicators.md",
      "narrative": null,
      "content": "Table 7.3 presents indicators recommended for all programmes intending to comprehensively \nmeasure and monitor QOC for people receiving HIV services. Web Annex B provides additional \nindicators for programmes with the capacity to adopt and sustain more indicators for more \nrobust QOC monitoring. The majority of indicators highlighted in this subsection have been \nrecommended in Chapters 2, 3, and 4 of these guidelines and draw from the minimum dataset \n(Web Annex A). \nTable 7.3 Priority indicators for quality of care\nRef. no.\nShort name\nIndicator definition\nQOC domain\nCare stage: prevention\nPR",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents Table 7.3, the priority indicators recommended for monitoring quality of HIV care across prevention, testing, treatment and other care stages, such as linkage to treatment, viral load suppression and coverage of differentiated service delivery models. It notes that more indicators are in a web annex and that most come from earlier chapters and the minimum dataset. It ends by urging that quality concepts be built into national strategic information frameworks and routine systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-169",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Community-led monitoring",
      "pageStart": 305,
      "pageEnd": 307,
      "target": "../sections/sec-169-73-community-led-monitoring.md",
      "narrative": null,
      "content": "Community engagement of people living with and affected by HIV through CLM is fundamental \nto using data to improve the quality of HIV and related services. Community engagement \ncreates an enabling environment for stakeholders to work together to address health-\nrelated issues and promote well-being and, ultimately, to achieve positive health impact \nand outcomes (23). \nCLM is an accountability and advocacy strategy with the primary objective of improving \nquality, accessibility and utilization of HIV services by holding duty-bearers and health care \nservice providers accountable for the qual",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes community-led monitoring as an accountability and advocacy strategy led by organisations of people living with HIV and key populations to improve the quality and accessibility of services. It distinguishes it from community-based service delivery and stresses that communities should set its focus free from outside influence. The section explains how its findings, combined with routine person-centred data, can reveal gaps that might otherwise be missed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-170",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Logistics management information systems",
      "pageStart": 307,
      "pageEnd": 309,
      "target": "../sections/sec-170-74-logistics-management-information-systems.md",
      "narrative": null,
      "content": "An uninterrupted supply of ARV drugs and diagnostics commodities for HIV prevention, testing \nand treatment of people living with HIV is a prerequisite for all HIV programmes. An effective \nand sustainable supply chain system for drugs and other commodities is complex and has many \nstakeholders. A well-run distribution system keeps drugs in good condition, rationalizes drug \nstorage points, uses transport as efficiently as possible, reduces theft and fraud and provides \ninformation for forecasting needs. \nThe supply of ARVs must be continuous and uninterrupted at all service delivery points.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why an uninterrupted supply of antiretroviral drugs and diagnostics is essential to HIV programmes and what a good distribution system achieves. It notes that drug dispensing data can measure multi-month dispensing under differentiated service delivery. It argues that linking logistics management information systems with deduplicated, de-identified patient-level data helps avoid wastage and stock-outs, with quarterly review recommended.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-171",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Health facility assessments",
      "pageStart": 309,
      "pageEnd": 310,
      "target": "../sections/sec-171-75-health-facility-assessments.md",
      "narrative": null,
      "content": "The ready availability and good quality of health services are integral to strong primary health \ncare and universal health coverage and contribute to achieving the Sustainable Development \nGoals. Data collected from health facility assessments monitor the capability and performance \nof health facilities and can support evidence-based decision-making in health sector reviews, \nplanning, management and policy-making. The domains assessed can range from services \nprovided to whether practice follows policies and protocols and whether the environment \nsupports providers in providing high-quality",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how health facility assessments monitor the availability and readiness of HIV services, including staff, equipment, medicines and diagnostics, and warns that private facilities are often under-represented in samples. It mentions tools such as the Service Availability and Readiness Assessment and includes part of a case study from Malawi on electronic medical records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-172",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Civil registration and vital statistics",
      "pageStart": 310,
      "pageEnd": 310,
      "target": "../sections/sec-172-76-civil-registration-and-vital-statistics.md",
      "narrative": null,
      "content": "CRVS systems provide the data required on the number of births in the population as well \nas deaths and causes of death for the HIV-related mortality measure. The completeness and \naccuracy of vital registration data vary considerably among countries. The usability of CRVS \ndata for monitoring the health sector response to HIV depends on strict compliance with \nreporting requirements; reporting both primary and underlying cause of death; confidentiality \nof the deceased and his or her family when reporting stigmatized causes of death such as \nHIV; and the consistency, completeness and accuracy",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how civil registration and vital statistics provide data on births, deaths and causes of death for HIV mortality, and the conditions for these data to be usable, such as confidentiality and completeness. It notes that verbal autopsy and other special studies, and linking data systems, can fill gaps.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-173",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Population-based survey data",
      "pageStart": 310,
      "pageEnd": 311,
      "target": "../sections/sec-173-77-population-based-survey-data.md",
      "narrative": null,
      "content": "Population-based surveys are very important for capturing the situation of people who are \nnot engaged in health services. For example, if a country has ART treatment coverage of \n70%, understanding why the remaining 30% are not engaged in care is possible only through \na population-based survey that reaches a representative group of people not engaged with \nhealth services. Thus, surveys complement routine programme data. \nMany guidance documents describe the proper design, sampling, data collection and analysis \nof population-based surveys covering HIV both in the general population (for exa",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that population-based surveys capture people not reached by health services and complement routine data, listing survey types such as DHS, AIS, PHIA, bio-behavioural surveys and the Stigma Index. It sets out considerations for using survey indicators, including their cost, infrequency, limited geographic precision and the difficulty of surveying children and adolescents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-174",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mathematical modelling",
      "pageStart": 311,
      "pageEnd": 312,
      "target": "../sections/sec-174-78-mathematical-modelling.md",
      "narrative": null,
      "content": "Estimating the number of people newly infected with HIV or who have died of AIDS-related \ncauses is important for understanding the potential impact and costs associated with \nimplementing interventions and services for HIV prevention, testing and treatment. Using \nmodelled estimates is helpful because it is impossible to directly count the numbers of \npeople living with HIV, of people who are newly infected with HIV or of people who have \ndied from HIV-related causes. Models incorporate data from geographical and population-\nspecific surveys and other forms of surveillance data (for example,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why modelled estimates are needed for numbers of people living with HIV, new infections and AIDS deaths, and how models such as Spectrum AIM combine survey, surveillance and programme data. It notes that models allow comparison over time and across countries and can answer other policy questions, and recommends including model results in regular data reviews.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-175",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data quality review, triangulation and use",
      "pageStart": 312,
      "pageEnd": 313,
      "target": "../sections/sec-175-79-data-quality-review-triangulation-and-use.md",
      "narrative": null,
      "content": "A systems approach to improving data quality includes establishing a data quality review \n(DQR) process. Such a process will help countries be more confident that their data accurately \nreflect the status of the populations served and the performance of their programmes. Through \na collaborative effort of WHO, the Global Fund and Gavi, a harmonized, health sector-wide \nframework for DQR was developed (37). It is applicable from the level of health facilities up to \nthe national level. The DQR framework complements systems in place for routine monitoring, \nsupervision and evaluation of programm",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the harmonized data quality review framework developed by WHO, the Global Fund and Gavi, recommended for integration into health information systems and at least annual national review. It lists the quality dimensions assessed, such as completeness, timeliness and internal and external consistency, and notes that subnational and facility managers may review data more often.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-176",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evaluation and operational research",
      "pageStart": 313,
      "pageEnd": 314,
      "target": "../sections/sec-176-710-evaluation-and-operational-research.md",
      "narrative": null,
      "content": "In addition to routine programme data, programmes need regular evaluations and a system \nfor conducting operational research to learn from implementation and answer complex \nquestions or to test new approaches in service delivery. Evaluation, operational research \nand implementation science employ research methods to address such questions, which \ncomplement routine data review as a data-driven approach to continuous quality improvement \nand service coverage.\nSince resources are limited, it is crucial to focus investment on programmes and services \nthat are appropriate to needs, can be well-im",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses that HIV programmes need regular evaluation and operational research alongside routine data, with a prioritized evaluation agenda and studies managed as formal projects, noting that individual-level data are better suited to research questions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-177",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 314,
      "pageEnd": 317,
      "target": "../sections/sec-177-references.md",
      "narrative": null,
      "content": "1.\t\nWorld Health Organization, Centers for Disease Control and Prevention, Joint United \nNations Programme on HIV/AIDS, FHI 360. Biobehavioral survey guidelines for populations \nat risk for HIV. Geneva: World Health Organization; 2017 (https://www.who.int/\npublications/i/item/978-92-4-151301-2, accessed 24 June 2022).\n2.\t\nJustman JE, Mugurungi O, El-Sadr WM. HIV population surveys—bringing precision to the \nglobal response. N Engl J Med. 2018;378:1859-61. \n3.\t\nDemographic and health surveys (DHS) program [website]. Rockville (MD): ICF; 2022 \n(https://dhsprogram.com/, accessed 14 July 2022).\n4.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the chapter on HIV data sources, citing WHO guidance on surveys, quality of care and consolidated HIV guidelines, survey programmes such as DHS and AIS, and data collection tools.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-178",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 8 – Priority indicators",
      "pageStart": 317,
      "pageEnd": 318,
      "target": "../sections/sec-178-chapter-8-priority-indicators.md",
      "narrative": null,
      "content": "PRIORITY INDICATORS\n8\n8.1\t Introduction\b\n288\n8.1.1 Disaggregation\b\n288\n8.1.2 Time periods\b\n289\n8.1.3 Inclusion of community-based service data\b\n290\n8.2\t Priority indicators by programme area\b\n291\n8.2.1 HIV prevention\b\n291\n8.2.2 HIV testing services\b\n313\n8.2.3 HIV treatment\b\n325\n8.2.4 TB/HIV\b\n344\n8.2.5 Differentiated service delivery\b\n353\n8.2.6 Sexually transmitted infections \b\n359\n8.2.7 Viral hepatitis\b\n373\n8.2.8 Cervical cancer\b\n382\n8.2.9 HIV incidence \b\n386\n8.2.10 AIDS-related mortality\b\n387\n8.2.11 Stigma and discrimination\b\n388\nCHAPTER 8 – PRIORITY INDICATORS",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The contents page of Chapter 8 on priority indicators, listing sections by programme area from HIV prevention and testing to hepatitis, cervical cancer and stigma.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-179",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 318,
      "pageEnd": 318,
      "target": "../sections/sec-179-81-introduction.md",
      "narrative": null,
      "content": "This chapter details the recommended priority indicators, including core indicators, organized \nby five programme areas: \n•\t prevention, including indicators on condom programming, PrEP, PEP, needle-syringe \nprogrammes, OAMT, VMMC;\n•\t testing and treatment, including indicators on HIV testing, HIV treatment and care, vertical \ntransmission, TB/HIV, multi-month ARV dispensing; \n•\t related infections, including indicators on STIs, viral hepatitis and cervical cancer;\n•\t impact, including indicators on HIV incidence and AIDS-related mortality;\n•\t stigma and discrimination. \nFor each indicator the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Chapter 8, which details priority and core indicators organized under prevention, testing and treatment, related infections, impact, and stigma and discrimination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-180",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Disaggregation",
      "pageStart": 318,
      "pageEnd": 319,
      "target": "../sections/sec-180-811-disaggregation.md",
      "narrative": null,
      "content": "8.1.1 Disaggregation\nDisaggregated data are needed to assess equity and performance in health service access \nand health outcomes among different geographic and sociodemographic subpopulations \nand important patient subgroups. Routine assessment of equity in service delivery and \nquality across groups is fundamental to honouring the commitment of the HIV response to \nequity. In terms of improving programme performance, the fastest way to achieve overall \nprogramme targets lies in identifying and closing the gaps of the most underserved groups. \nThe subpopulations benefiting from disaggregated",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains why data should be disaggregated by geography, age, gender, priority population and patient group to assess equity and close gaps for underserved groups. It discusses age bands and other disaggregation categories and the need for consistent categories across indicators. It ends by warning that fine-grained disaggregation in small areas can breach confidentiality where stigma or criminalization are common.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-181",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Time periods",
      "pageStart": 319,
      "pageEnd": 320,
      "target": "../sections/sec-181-812-time-periods.md",
      "narrative": null,
      "content": "In general, the priority indicators use an unspecified reporting period. They can be calculated \nover different periods of time to answer programme management questions at different levels \nand as required for differing reporting purposes. Some indicators have specific reporting \nperiods (for example, “in the last 12 months”) that are important because they reflect \nrecommended service delivery guidelines or the way that the indicator is collected. \nThe collection of person-centred data and tracking individuals means that programmes can \nlook at uptake of services over time. For example, in ad",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that most priority indicators have no fixed reporting period and can be calculated over different periods, while some track individuals' service use over time, such as follow-up viral load testing, which may need longitudinal registers or digital systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-182",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Inclusion of community-based service data",
      "pageStart": 320,
      "pageEnd": 321,
      "target": "../sections/sec-182-813-inclusion-of-community-based-service-data.md",
      "narrative": null,
      "content": "Although a majority of routine health information systems are based at health facilities, \neffective programme monitoring and programme management also require data from health \nservices delivered in community-based settings. Increasingly, data systems must be able to \ncapture and integrate data on the delivery of community-based services, delivered via mobile \nor satellite clinics and often by peer or outreach workers.\nAvoiding double counting of individuals reported through community-based services and \nfacility-based services is essential – for example, when patients are referred from commu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses that monitoring systems should capture community-based service data and avoid double counting people referred between community and facility services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-183",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority indicators by programme area",
      "pageStart": 321,
      "pageEnd": 321,
      "target": "../sections/sec-183-82-priority-indicators-by-programme-area.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-184",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV prevention",
      "pageStart": 321,
      "pageEnd": 343,
      "target": "../sections/sec-184-821-hiv-prevention.md",
      "narrative": null,
      "content": "PRV.1 Condoms distributed \nTotal number of condoms distributed during the reporting period\nWhat it measures\nThis indicator measures the number of condoms distributed through different modalities.\nRationale\n•\t Proactive distribution of condoms is a strategy for ensuring adequate availability.\n•\t By analysing the proportion of condoms distributed through different modalities, \nnational programmes can optimize their investment in socially marketed and public-sector \n(that is, free) condom distribution.\nNumerator\nTotal number of condoms distributed and sold during the reporting period\nDenominator",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority indicators for HIV prevention, each with what it measures, rationale, numerator, denominator, measurement method and disaggregation. It opens with condoms distributed and people receiving pre-exposure prophylaxis, and covers the range of prevention services. It ends with indicators on condom use at last sex for the general population and key populations, with notes on survey sources and adapting recall periods to local context.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-185",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV testing services",
      "pageStart": 343,
      "pageEnd": 355,
      "target": "../sections/sec-185-822-hiv-testing-services.md",
      "narrative": null,
      "content": "HTS.1 People living with HIV who know their HIV status (first 95)\nNumber and % of people living with HIV who know their HIV status\nWhat it measures\nThis measures the number and percentage of people living with HIV who have been tested and \nknow their HIV status.\nRationale\n•\t Knowledge of HIV status is the entry point for people living with HIV to treatment and the \ncontinuum of care, and for those who test HIV-negative and remain at elevated risk of HIV \nacquisition, to prevention interventions. \n•\t Disaggregated estimates can reveal gaps in access to testing among important groups of \npeople",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority indicators for HIV testing services, starting with the number and percentage of people living with HIV who know their status (the first 95). It explains how to estimate this from case surveillance or models and how to deduplicate records. Further indicators cover testing services and yield. It ends with a new indicator on HIV retesting coverage among key populations, measured through survey questions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-186",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV treatment",
      "pageStart": 355,
      "pageEnd": 374,
      "target": "../sections/sec-186-823-hiv-treatment.md",
      "narrative": null,
      "content": "ART.1 People living with HIV on ART\nNumber and % of people on ART among all people living with HIV at the end of the \nreporting period\nWhat it measures\nMeasures progress towards providing ART to all people living with HIV, that is, treatment \ncoverage, taking into account total attrition during the reporting period.\nRationale\n•\t WHO currently recommends treatment for all people living with HIV to achieve viral \nsuppression. \n•\t This indicator is central to accountability for national health sector strategic plans, effective \nprogramme management and donor programming. \n•\t This indicator is ess",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority indicators for HIV treatment, starting with the number and percentage of people living with HIV on antiretroviral therapy, linked to the second 95 target. It explains how to calculate the numerator accounting for attrition and which denominators to use. Further indicators cover treatment outcomes and vertical transmission. It ends with HIV prevalence among antenatal clinic attendees and the conditions under which these data can be used for surveillance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-187",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB/HIV",
      "pageStart": 374,
      "pageEnd": 383,
      "target": "../sections/sec-187-824-tbhiv.md",
      "narrative": null,
      "content": "TBH.1 TPT initiation\nNumber and % of eligible people living with HIV on ART who initiated TB preventive treatment\nWhat it measures\nThis indicator measures the extent to which people on ART initiated treatment for latent \nTB infection.\nRationale\n•\t TB preventive treatment (TPT) is a critical component of preventing TB-related morbidity \nand mortality among people living with HIV. \n•\t In the wake of recent high-level global commitments and targets, this is a critical period to \ntrack the progress that countries have made in scaling up TPT coverage.\nNumerator \nNumber of ART patients who initiated",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority indicators for TB/HIV, starting with initiation of TB preventive treatment among eligible people on ART and a formula for calculating eligibility. Disaggregation by gender, age and regimen is specified. The indicators follow a screening cascade for high-burden settings. They end with the share of people newly started on ART and diagnosed with active TB who began TB treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-188",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Differentiated service delivery",
      "pageStart": 383,
      "pageEnd": 389,
      "target": "../sections/sec-188-825-differentiated-service-delivery.md",
      "narrative": null,
      "content": "DSD.1 Multi-month ARV dispensing (NEW) \n% of people living with HIV and currently on ART who are receiving multi-month dispensing of \nARV medicine during the reporting period\nWhat it measures\nPercentage of all people living with HIV and currently on ART who received a multi-month \nsupply of ARV medicine (as specified below) at their most recent ARV medicine pick-up.\nRationale\n•\t The recommendation for people living with HIV who are established on ART (see \n“Definitions,” below) to receive multiple months of ARV medicines is a key component \nof care that responds to the needs and preferences of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority indicators for differentiated service delivery, starting with a new indicator on multi-month dispensing of antiretroviral medicines and its rationale for adherence and system efficiency. It explains numerators by months of supply dispensed. It ends with viral load suppression among people enrolled in differentiated ART models, monitored where electronic systems exist.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-189",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Sexually transmitted infections",
      "pageStart": 389,
      "pageEnd": 403,
      "target": "../sections/sec-189-826-sexually-transmitted-infections.md",
      "narrative": null,
      "content": "STI.1. Syphilis testing coverage (NEW)\n% of people tested for syphilis during the reporting period\nWhat it measures \nA: \u0007% of people attending HIV prevention services who were tested for syphilis during the \nreporting period\nB: \u0007% of people living with HIV who were tested for syphilis during the reporting period\nC: % of pregnant women who were tested for syphilis during the reporting period \nRationale\n•\t Measuring the burden of syphilis among people living with HIV and among populations at \nelevated risk of HIV acquisition can help national planners determine the resources needed \nto address b",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the priority indicators for sexually transmitted infections, starting with a new indicator on syphilis testing coverage among people using HIV prevention services, people living with HIV and pregnant women. Each indicator gives rationale, numerator, denominator, measurement and disaggregation. Further indicators cover STI diagnosis and treatment. The section ends with repeat diagnoses of the same STI syndrome, which may signal inadequate treatment or an untreated partner.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-190",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Viral hepatitis",
      "pageStart": 403,
      "pageEnd": 412,
      "target": "../sections/sec-190-827-viral-hepatitis.md",
      "narrative": null,
      "content": "HEP.1. HBV test coverage (NEW)\n% of people who were tested for hepatitis B surface antigen (HBsAg) during the reporting period \n(laboratory-based test or rapid test) \nWhat it measures\nA: \u0007% of people attending HIV prevention services who were tested for HBsAg during the \nreporting period (laboratory-based test or rapid test)\nB: \u0007% of people living with HIV who were tested for HBsAg during the reporting period \n(laboratory-based test or rapid test)\nC: \u0007% of pregnant women who were tested for HBsAg during the reporting period \n(laboratory-based test or rapid test)\nRationale\n•\t Measuring the HBV",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines new viral hepatitis indicators for HIV strategic information, starting with hepatitis B surface antigen testing coverage among people using HIV prevention services, people living with HIV and pregnant women. For each indicator it sets out what is measured, the rationale, numerator, denominator, measurement method and disaggregation. Further indicators cover hepatitis B and C treatment and outcomes, such as people with HIV cured of hepatitis C, with disaggregation by medicine type and region. Footnotes clarify gender categories and data confidentiality considerations for key populations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-191",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cervical cancer",
      "pageStart": 412,
      "pageEnd": 416,
      "target": "../sections/sec-191-828-cervical-cancer.md",
      "narrative": null,
      "content": "CCA.1 Cervical cancer screening (NEW) \nNumber of women living with HIV who were screened for cervical cancer using any screening test \nWhat it measures\nProgress towards scaling up population-based screening for the prevention of cervical cancer \namong women living with HIV.\nRationale\nTo measure progress towards scaling up screening for the prevention of cervical cancer among \nwomen living with HIV. Since the screening interval between tests depends on the test used, \nthe number of women screened may vary from year to year. \nNumerator\nNumber of women living with HIV who were screened for cervic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines new cervical cancer indicators for women living with HIV, including the number screened with any test, with guidance on counting each woman once and using facility registers. Further indicators address follow-up and treatment of screen-positive women and survival 12 months after a cervical cancer diagnosis, disaggregated by age, stage and area. The section ends by introducing a cervical cancer survival indicator.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-192",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV incidence",
      "pageStart": 416,
      "pageEnd": 417,
      "target": "../sections/sec-192-829-hiv-incidence.md",
      "narrative": null,
      "content": "INC.1 HIV incidence\nEstimated number of people newly infected with HIV per 1000 uninfected population\nWhat it measures\nThis indicator measures progress towards ending the HIV/AIDS epidemic and achieving the goal \nof “zero new infections”.\nRationale\nThe overarching goal of the global HIV/AIDS response is to reduce the number of people newly \ninfected to fewer than 200 000 by 2030.\nNumerator\nNumber of people newly infected with HIV during the reporting period\nDenominator \nTotal number of uninfected population (or person-years exposed)\nMethod of measurement \nCan be measured from individual-level",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the HIV incidence indicator as new infections per 1000 uninfected people, with its rationale, measurement through programme data or modelling tools such as Spectrum, and disaggregation by gender, age and route of transmission.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-193",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "AIDS-related mortality",
      "pageStart": 417,
      "pageEnd": 418,
      "target": "../sections/sec-193-8210-aids-related-mortality.md",
      "narrative": null,
      "content": "MOR.1 AIDS mortality \nTotal number of people who have died from AIDS-related causes per 100 000 population\nWhat it measures\nThis indicator measures the impact of HIV prevention, care and treatment programmes.\nRationale\nIn the era of “Treat All”, effective diagnosis and treatment of people living with HIV should \ngreatly reduce deaths due to AIDS-related causes.\nNumerator\nEstimated number of people dying from AIDS-related causes during the calendar year\nDenominator \nTotal population, regardless of HIV status\nMethod of measurement \nIndividual-level programme data, civil registration and vital st",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the AIDS mortality indicator as AIDS-related deaths per 100,000 population, explaining its purpose, data sources such as vital registration or modelling, and disaggregation by gender, age and key population.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/prose-sec-194",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Stigma and discrimination",
      "pageStart": 418,
      "pageEnd": 424,
      "target": "../sections/sec-194-8211-stigma-and-discrimination.md",
      "narrative": null,
      "content": "SDC.1 Avoidance of health care due to stigma and discrimination \n(key populations)\n% of key population members who avoid health care because of stigma and discrimination.\nWhat it measures\nThis indicator measures the extent to which perceived stigma and discrimination in health care \nsettings results in members of key populations avoiding health care.\nRationale\n•\t Health care settings are one of the most common places that members of key populations \nexperience discrimination. \n•\t Tracking the proportion of key populations that avoid health care due to stigma and \ndiscrimination provides manage",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines indicators on avoidance of health care because of stigma and discrimination among key populations and among people living with HIV, using survey questions about avoiding testing, care or treatment. It gives numerator, denominator, data sources such as the Stigma Index, and disaggregation, and ends with WHO contact details and the ISBN.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360948/blocks/figure-img-p424-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 424,
      "pageEnd": 424,
      "target": "../images/img-p424-1.webp",
      "narrative": "draft",
      "content": "ISBN barcode with the number 9789240055315.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
